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 Gene delivery by viruses, specifically AAV, offers an efficient way to safely supply 
exogenous DNA to cells long term in vivo. The ability of AAV to infect post-mitotic neurons 
makes it a great vector for neuroscience applications. The small, accessible, and 
compartmentalized nature of the eye have made it an ideal organ for gene therapy research. 
The route of delivery into the eye largely dictates the tropism and distribution of AAV, but never 
has the numerous routes been compared using a single vector and titer. We injected scAAV2 
containing CMV-GFP transgenes into the various compartments (IS, IC, IVIT, SR, SC) within 
the eyes of mice. Anterior chamber injections lead to fluorescence mainly in the anterior portion 
while the posterior injections lead to transduction of the ciliary body and retina. Transduction of 
the retina is of interest to potentially treat retinal degenerative disorders. IC and IVIT injections 
led to transduction of the inner retina and SR and SC injections transduced the outer retina, with 
the best fluorescence detected by either SR or IVIT delivery. Many AAV serotypes are known to 
efficiently transduce the retina when delivered to the SR space, but show limited success when 
delivered to the vitreous due to the inner limiting membrane (ILM). Therefore, a collection of 
capsid mutants was used to understand the trafficking patterns of AAV in the retina. 
Transduction of AAV by SR delivery occurred by a heparan sulfate (HS) independent 
mechanism whereas IVIT transduction was highly dependent on HS binding. This was due to 
the accumulation of vector at the ILM where HS proteoglycan (HSPG) was abundantly found. 
For clinical relevance, this mechanism was tested in human ex vivo retinas and determined to 
iv 
 
be conserved. The HS-binding motif enhanced the transduction of other AAV serotypes (AAV1, 
AAV8) by the same mechanism. To determine the extent of HS-binding on tropism, capsid 
motifs from other AAV serotypes were used to create chimeric AAV2 capsids. A motif from 
AAV1 enhanced the transduction along the retinal vessels whereas the galactose motif from 
AAV9 lead to Müller glial specific transduction. Together, the double chimera showed 
characteristics of both motifs that completely ablated native AAV2 transduction. Through 
rational engineering of AAV using various capsid motifs, we have identified motifs involved in 
retinal trafficking and generated a novel capsid variant for targeted and enhanced transduction 
within the retina by IVIT delivery.  
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CHAPTER 1: Introduction to AAV and its use in gene delivery 
1.1 The benefits of using AAV  
The ability to express exogenous DNA within a cell allows researchers or clinicians to 
study ectopic gene expression or provide healthy genetic copies to genetically-diseased cells. 
The phosphate groups on the DNA backbone provide a polarity to the DNA molecule that allow 
it to be moved by applying a magnetic field, commonly done during electroporation. In vitro, this 
method is commonly used to transform bacterial and eukaryotic cells, but its use in vivo is 
limited to dividing cells and is not a viable delivery method for human trials [1]. To circumvent 
these shortfalls, viruses offer a natural vector that can efficiently deliver DNA to cells. Numerous 
virus types have been domesticated and tested for their ability to transduce tissues or cells of 
interest.  Viruses like lentivirus led the way for early viral gene delivery and opened the door to 
the use of other viral vectors, like adenovirus [2]. Typically, these viral vectors were based off a 
pathogenic virus that were well characterized. Although efforts have been made to improve the 
safety of these vectors by removing much of the viral genome [3, 4], the viral components still 
can evoke a pathogenic response within the host. Therefore, the majority of the gene therapy 
field has flocked to viruses with inherently better safety profiles. One such viral vector is Adeno-
associated virus (AAV) due to its ability for site-specific integration [5], non-pathogenic [6] and 
non-immunogenic nature which is a huge benefit in terms of safety for trials. The benign nature 
of AAV is evidenced by the large human population that has been previously exposed to AAV 
without any complications [7]. In addition, the replication of AAV is dependent on the co-
infection of specific viruses (e.g. adenovirus (Ad), herpes simplex virus [8, 9]), which reduces 
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the risk of vector mobilization. Together, these attributes make AAV a good vector for gene 
delivery and have led to research on much of the AAV biology. 
1.2 The AAV life cycle and biology 
AAV consists of a linear, single-stranded DNA genome surrounded by a viral protein 
capsid. The capsid topography and motifs promote the interaction with glycans and receptors on 
the cell surface needed for viral entry (Figure 1.1). These glycan and receptor interactions are 
discussed in greater detail below. Through receptor-mediated endocytosis, AAV virions enter 
the cell surrounded by a clathrin-coated vesicle. The vesicle is trafficked along microtubules 
toward the perinuclear region using dynein motor proteins [10] as the endosome begins to 
acidify. The acidification exposes the phospholipase A2 domain tucked inside the capsid for the 
virion to escape [11]. Once out of the endosome, AAV uses actin filaments [12] and nuclear 
pore complexes, like importin-β [13], to enter the nucleus. Inside in the nucleus, the viral 
genome becomes exposed for second-strand synthesis [14]. Virions that fail to escape 
endosomes become degraded by proteasomes. 
The AAV genome is protected inside the viral capsid until it reaches the nucleus (Figure 
1.2). Once inside the nucleus, the capsid breaks down to expose the genome to the cellular 
machinery [14]. The ~4.7kb genome is a single-stranded DNA molecule [15] capped at each 
end by an inverted terminal repeat (ITR). The single-stranded molecule is first converted to a 
double-stranded molecule through second-strand synthesis. The ITRs are important in forming 
a secondary structure that aides in the initiation of second-strand synthesis. After the second 
DNA strand has been synthesized, and with the co-infection with one of the viruses stated 
above, transcription of the two ORFs (rep and cap) generates various products via three internal 
promoters: p5, p19, p40. The translation of those products yields the eight proteins needed for 
AAV replication and assembly [16]. The rep gene is translated into four Rep proteins needed for 
nearly every aspect of AAV genome replication and packaging. The cap gene is involved in the 
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production of proteins needed to compose the AAV capsid structure. The cap gene produces 
one AAP protein and three capsid viral proteins (VP1, VP2, and VP3) from the p40 promoter 
(Figure 1.2). The VP1 protein contains the sequences of VP2 and VP3, and VP2 contains the 
sequence of VP3. The three proteins come together, via the AAP protein, in a ratio of 
approximately one VP1 and one VP2 to 10 VP3 which form the 60-subunits needed to make the 
T = 1 icosahedral structure [17].  
When these proteins come together, VP3 is surface exposed with the remaining VPs 
predicted to be tucked into the internal part of the capsid [17]. The VP3 has eight β-barrels 
which twist around in the monomer of the AAV capsid (Figure 1.3). The twists in the monomer 
form loops, known as variable regions, that are important to the capsid monomers assembly. 
When the subunits come together to form the viral capsid, the topography of the capsid form 
protrusions (threefold axis of symmetry), valleys (twofold axis of symmetry), and pores (fivefold 
axis of symmetry). Important to this topography is the threefold axis of symmetry protrusions 
(shown in blue, Figure 1.3). The regions around the protrusions are responsible for the 
interaction of AAV virion with the cell glycans. Various AAV serotypes exist which differ in their 
variable regions and mediate interaction with various glycans on the cell surface. 
1.3 AAV capsid motifs for glycan binding 
Glycans and receptors have been elucidated for the transductions several of the AAV 
serotypes (Table 1.1). Heparan sulfate (HS) proteoglycan (HSPG) is used by both rAAV2 and  
rAAV3 [18]. rAAV6 displays a dual glycan interaction with HSPG and sialic acid (SIA); however, 
HSPG binding alone is insufficient for cellular entry [19]. Various linkages of sialic acid are 
important for the transduction of rAAV1, rAAV4, and rAAV5 serotypes [19, 20]. N-linked 
galactose (GAL) is used for the transduction of rAAV9 serotype [21]. These binding motifs tend 
to involve the base of the protrusion at the threefold axis of symmetry (Figure 1.4).  For 
example, rAAV2 HS-binding motif is a patch of basic residues at the base of the threefold axis 
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of symmetry protrusions. Glycans expressed on the cell surface, in part, dictate the tissue and 
cellular tropism observed with the various AAV capsids. By altering these motifs, the 
transduction profile can be modified. (e.g. ablating the HS-binding motif in rAAV2 alters the 
transduction of away from the HSPG-rich liver tissue [22]). In addition to the attachment to these 
glycans, AAV serotypes interact secondarily with cell receptors (Table 1.1). These co-receptors 
include growth factor receptor (FGFR, HGFR, PDGFR, EGFR), integrins, and laminin receptors 
[18, 23, 24]. 
1.4 Recombinant AAV (rAAV) as a vector for gene delivery 
rAAV can be domesticated for the purposes of DNA gene transfer through the removal 
of the two genes replacing them with a desired transgene. Because only the ~145bp ITRs are 
necessary to produce rAAV, the 4.7kb genomes can be almost entirely removed to effectively 
package a transgene of a similar size. To produce rAAV, three plasmids are supplied to cells 
through transfection methods [25]. The rep and cap genes are supplied in trans to the plasmid 
containing the transgene flanked by ITRs. The 3’ ITR is used to package the genome into the 
preformed capsids [16], and the lack of ITRs on the rep/cap plasmid prevents the formation of 
wild-type AAV in the production of rAAV. The ITR isolated from AAV2 allow the transgenes to 
be packaged into multiple AAV capsids through a process known as pseudotyping [26]. This 
allows transgene expression to be accurately assessed among the different AAV serotypes. The 
third plasmid supplies Ad genes (i.e. E1a, E2a, E1b, E4) needed to start AAV production [27]. 
Using biochemical purification methods (e.g. density gradient, column chromatography), rAAV 
can be then purified from these plasmids and other cellular proteins to yield concentrated, pure 
viral reagent that can infect mitotic and post-mitotic cells for long-term gene expression on the 
order of years [25]. 
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1.5 Self-complementary rAAV transgene cassette 
rAAV particles that successfully traffic to the nucleus and uncoat must then convert the 
single-stranded genome to a double-stranded DNA molecule. This second-strand synthesis is 
said to be rate-limiting in the expression of the transgene [28]. To circumvent this bottleneck, a 
self-complementary (scAAV) construct [29] can be used. To produce the scAAV, the TRS at the 
5’ end ITR (Figure 1.2) is mutated to no longer promote the nicking of the double-stranded DNA 
molecule. The self-complementary DNA is packaged into the capsid to form scAAV [30]. The 
total amount of DNA packaged into the rAAV capsid remains constant at <5kb; therefore, 
scAAV package approximately half the size (~2.5 kb) of the native single-stranded AAV 
(ssAAV). scAAV shows increased transduction efficacy that is faster and more stable than the 
classic ssAAV construct [29-32]. In addition to the increased transduction efficacy, scAAV can 
lead to transgene expression of cells not seen with ssAAV, indicating that some cell populations 
may not possess the molecular machinery needed for second-strand synthesis [33]. scAAV is 
becoming more popular in the use of gene therapy to assess capsid transduction and for 
transgenes small enough to fit its size constraint.  
1.6 Gene transfer in the nervous system 
The post-mitotic nature of most of the nervous system limits the viral vectors capable of 
being used for in vivo gene transfer [34]. The ability of rAAV to transduce both post-mitotic and 
mitotic cells makes it of particular interest to the neuroscience community. Not only is rAAV 
capable of transducing nervous tissue, the various capsids display differences in their 
transduction profile based on the serotype [35]. These differences are advantageous when 
looking for targeted transduction of specific cell types or regions within the nervous system. 
There are two major groups that comprise the nervous tissue: central nervous system (CNS) 
and peripheral nervous system (PNS). The CNS consists of the brain and spinal cord which are 
protected by the skull and vertebrate, respectively. The PNS is the remaining neurons and 
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supporting cells that innervate the internal organs and muscles. Although the PNS is more 
accessible than the CNS, the compact nature of the CNS and the numerous disorders that 
affect this part of nervous system have made it the focus for gene therapy applications. 
Specifically, sensory organs of the CNS, like the eyes, are of particular interest because they lie 
outside the skull, are small, and easily accessible. 
1.7 Retinal gene therapy 
Vision relies on a healthy retina, a visual pathway from the eyes to the brain, and brain 
structures needed for visual processing. While there are some disorders that affect the latter 
structures of vision, the retina has a large variety of heritable diseases. The retina is particularly 
interesting because of its laminar structure (Figure 1.5) and the majority of diseases that affect 
the outer retina. The term outer retina here is defined as the photoreceptors (PR) in the outer 
nuclear layer (ONL) and retinal pigment epithelium (RPE). Because the cells of the ONL are 
intimately responsible for the generation of the vision, treatment of these cells can provide a 
subjective readout of therapeutic success. In addition to this subjective analysis, several 
objective assessments can be done to measure retinal structure using optical coherence 
tomography (OCT), function using electroretinogram (ERG) and connectivity using functional 
magnetic resonance imaging (fMRI). Together, these attributes make retinal gene therapy a 
popular topic for clinicians and researchers. 
The conversion of light into a neuronal signal is accomplished in the retina, specifically 
by the PR. Light must be able to pass through the structures in the anterior eye (i.e. cornea and 
lens), through the vitreous, and through the retina before reaching the PR. These specialized 
structures must work in concert to focus light onto the retina. Two general types of PR exist in 
mammals: rods and cones. Rods are the PRs capable of sensing very low levels and are the 
most abundant cell type, capable of providing contrast although still a rough, black-and-white 
view of the world. Cones are active in high levels of light and are involved in color perception. 
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These cells are most abundant in the fovea in primates which provide high visual acuity. 
Although absent in mice, the cone-rich fovea in non-human primates make these animals 
important in the study of eyes similar in size and structure to humans. However, the structure 
and function of the retina is similar among mammals, making mice the preferred animal model 
to study genetic ocular pathologies. PR connect to a number of bipolar cells in the INL. The 
signal is then propagated to the RGC which have its soma in the GCL. The RGCs send their 
axons along the inner surface of the retina to exit the eye through the optic nerve head. This is 
also the exit site for the inner retinal vessels. The optic nerve then tracks from the eyes to the 
brain for visual processing.  
The focused efforts in retinal gene therapy have led to several clinical trials around the 
world, all showing promising safety results [36-39]. These trials come at the heels of large sets 
of preclinical data collected in multiple animal models [40-42]. To date, there are over a dozen 
clinical trials initiated using rAAV to treat the RPE of patients with an RPE65 protein deficiency 
[Clincialtirals.gov] known as Leber congenital amaurosis (LCA). LCA causes patients to become 
blind very early in life. Gene therapy treatment to these patients shows modest success 
mitigating visual loss and confirms that the virus is safe for human use [43, 44]. The clinical 
injections were performed surgically by subretinal delivery of vector because LCA2 involves 
pathology of the RPE. The treatment used rAAV2 to carry a hRPE65 gene to replace the 
defective endogenous rpe65 gene in the RPE cells. Initially, only the worse eye of each patient 
was treated to assess safety and tolerance. Studies have now moved forward to treat the 
contralateral eye [45], which yielded a synergic enhancement in self-reporting visual tests.  
1.8 Intraocular injection routes influence transduction 
The transduction profile in the retina can depend on the route of administration. A 
diagram of the eye shows the layers and the site of various injection routes (Figure 1.6). 
Currently, the standard delivery for retinal gene therapy is through the SR injection between the 
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ONL and RPE, which generally results in transduction of these two cell layers. The SR injection 
procedure takes advantage of the loose association between the ONL and RPE to detach the 
retina and cause a “bleb” where most the viral volume is located. The bleb typically resolves on 
its own after a day. The restructuring that the SR injection causes is tolerated in young, or 
mildly-pathogenic, cases, but in cases of severe pathology, SR injections may not be a viable 
option. For one, PRs that are dying may not survive being separated from their supporting RPE 
cells. Therefore, advanced retinal pathology can exclude cases of severe retinal degenerative 
from receiving treatment. Because retinal degeneration is non-uniformly distributed, it can be 
difficult to determine what area to treat. Because the bleb created by the injection causes an 
accumulation of vector in that area, leading to focal treatment of the retina. The ability to provide 
a larger area of treatment to the retina would hopefully save more retinal cells and retain a 
larger field of vision. Therefore, alternative delivery sites need to be identified and their 
transduction properties tested for in vivo retinal gene transfer. 
To circumvent these SR-delivery issues, rAAV is delivered to the vitreous. By delivering 
to the vitreal space, the vector spreads over a greater area of the retina while offering a less 
invasive and easier method. Although the IVIT injection is said to be less traumatic for the retina 
than the SR injection, IVIT delivery of rAAV can cause activation of Müller glia. Much of 
transduction observed with IVIT delivery is typically in the inner retina.  
More recently, injections into the SC space have been studied to take advantage of this 
space and its proximity to pathological cells of the outer retina. In large animals, the spread of 
SC injections can be greater than SR injections without retinal detachment. The tight junctions 
of the RPE and the OLM and may limit the spread of vector though the retina. The SC injection 
is difficult in the small mouse eye so only large animals have been used to study this injection. 
We attempted these injections and validated by fundoscopy, OCT, histology. Furthermore, we 




 Transduction from anterior ocular injection routes 
Anterior eye injections consist of IS and IC delivery routes. The IS injection showed a 
hazy fluorescence in the corneal where the injection occurred (Figure 1.7a). The cataract that 
formed during the injection procedure had cleared prior to evaluation for GFP (data not shown). 
No other GFP fluorescence was detected by fundoscopy in either the anterior segment or within 
the retina. IHC on IS-injected eyes showed no transduction of either the cornea, iris, ciliary 
body, or retina (Figure 1.7b-d) 
The transduction by the IC injection route was minimal in the anterior segment of the eye 
(Figure 1.8a). The retina showed transduction of RGCs by the GFP positive axons leading to 
the ONH in approximately half of the eyes injected for the study (arrowhead, Figure 1.8b). The 
transduced RGC somas not seen at the posterior retina by fundoscopy suggest transduced 
RGCs emanate from the peripheral retina. IHC performed on tissue revealed RGC transduction 
along the retina periphery and prominent ciliary body transduction (Figure 1.8c). Transduction 
observed in RGCs (arrow), and INL cells (arrowhead), could be seen in some retinas (Figure 
1.8d). The endothelium layer of cornea had faint GFP expression, but not in the other corneal 
layers (Figure 1.8e). Iris showed some GFP cells by IHC which were not detected by 
fundoscopy (data not shown).  
 Transduction by posterior ocular injection route 
IVIT delivery exposes rAAV to the inner retinal surface leading to transduction of RGC 
as seen by the GFP axons visible by fundoscopy (arrowhead, Figure 1.9a). There was no 
observable transduction in the anterior chamber or cornea by fundoscopy (data not shown). IHC 
showed predominant RGCs transduction (arrow, Figure 1.9b). Some RPE and INL cells were 
positive for GFP expression near the optic nerve (arrowhead). The transduced INL cells could 
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be Müller glia, bipolar, or horizontal cells (Figure 1.9c). No transduction was observed in the iris, 
cornea, or ciliary body (Figure 1.9d).  
SR injections resulted in detachment typically ~60% of the retina. GFP expression was 
most intense in the area of detachment, but transduction outside this area was also observed 
which looked like RPE cells (Figure 1.10a). Histology of these injected eyes confirmed RPE 
transduction along with transduction in the ONL and INL and few instances of RGC transduction 
(Figure 1.10b). There was very low GFP expression in ciliary body or cornea (Figure 1.10c, d). 
SR delivery leads to outer retinal transduction without much other expression. 
Delivery of vector to the SC space in mice was marked by spread of fluorescein by 
fundoscopy and lack of detachment seen with OCT (data not shown). Despite injection volume 
spread the GFP expression was not widely distributed (Figure 1.11a) and was RPE transduction 
in appearance. Histology of these SC-injected eyes revealed transduction mainly in the RPE 
and RGC layers (Figure 1.11b-d). Transduction of ciliary body was visible (Figure 1.11d), but 
not in the cornea (Figure 1.11e). 
1.10 Discussion 
From the various intraocular injection routes, we show the dramatic difference in rAAV2 
transduction of the retina (Table 1.2). In general, transduction was greatest in cells closest to 
the site of injection, as would be expected. Very little transduction was observed in tissue more 
distal from the site of injection, indicating that vector does not readily spread throughout the 
entire eye from a single injection route. Therefore, to sufficiently transduce the entire eye, 
multiple injections throughout the eye may be needed. Thankfully, there are few disorders which 
affect multiple structures within the eye. Many disorders affect the retina or RPE, which are 
sufficiently transduced by posterior intraocular injections: IVIT, SR, and SC. 
The SC injection lead to transduction mainly within the RPE. In some areas of the eye, 
transduction of all retinal layers was observed. The caveat of the SC data is the potential that 
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they were non-detaching SR injections. This multi-layer transduction may be due to the 
anterograde transport of rAAV2 [35]. Along with OCT and fundus imaging, histology of various 
regions of the eye were used to confirm that SR damage was not present. Since the retina is 
populated by post-mitotic cells, damage caused by the injection is visible in histology and 
prevents false-identified SC injections for analysis. The transduction of the SC injections 
showed distribution only over part of the mouse retina. This distribution phenomenon is like that 
of fluorescent particles in rabbit and ex vivo human eyes [46]. The small size of the mouse eye 
and lack of ultra-high resolution OCT make it difficult to perform a SC injection with confidence. 
The limited transduction and the difficulty of SC injection makes IVIT and SR the preferred 
routes from retinal transduction in the mouse. 
The IS injections resulted in a fluorescence that appeared confined to the general area 
where the vector was injected. Again, the injection into the stromal layer could not be validated 
by OCT; however, the opacity that was created by the injection was most likely within the thick 
stromal layer rather than the thin other layers (i.e. epithelium and endothelium). We were unable 
to determine the precise location of fluorescence within the cornea by fundoscopy, and the lack 
of GFP labelling on corneal sections by IHC did not indicate stromal transduction. Hippert et al. 
(2012) showed similar GFP corneal fluorescence with rAAV2 but did not explore further. The 
localized transduction of stromal layer makes sense given the two membranes which flank the 
stromal layers: Bowman’s layer and Descement’s membrane. These two layers may help to 
keep the vector confined to the stromal layer and; therefore, additional treatment of the cornea 
may be needed to help the vector spread over the multiple corneal layers. Various ssAAV 
vectors carrying the CMV-GFP transgene showed little stromal transduction by rAAV2, but other 
serotypes were better (rAAV8>rAAV1>rAAV2>rAAV5). 
The transduction of only the endothelial layer of the cornea by IC injection may be 
related to the Descement’s membrane. This membrane is found between the endothelial and 
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stromal layers and likely prevents the spread of vector into deeper layers of the cornea. To 
determine if this membrane prevents penetration, rAAV trafficking studies would need to be 
done. The structure of the cornea may not lend well to the penetration of vector and may 
encourage vector to travel through less resistive routes (i.e. through the trabecular meshwork or 
through the pupil/iris). By fundoscopy, the observed transduction of RGCs indicated vector can 
flow into the posterior portion of the eye. The volume of the anterior chamber is perhaps too 
small to accommodate the 1 µl of vector delivered to it, thereby encouraging the flow of vector 
into the vitreous chamber. The transduction of RGCs were only observed in about half of the 
eyes that received IC injection and could be related to the various amount of efflux in some 
injections. To reduce this leakage (both out of the injection site and into the vitreous) half of the 
volume was used to deliver the same amount of vector to the anterior chamber. Less leakage 
was observed out of the cornea and reduce the transduction of RGCs (data not shown). This 
indicates volume may be an important factor in determining the spread of vector throughout the 
eye. Other researchers have recently published showing IC injection without leakage by leaving 
an air bubble to sit at the injection site and prevent efflux out [47]. Using similar injection 
parameters testing a shortened CBA promoter (smCBA) showed robust expression in the 
trabecular meshwork and ciliary body by proteasome-resistant rAAV2 capsids [47].  
Delivery of vector to the vitreous resulted in transduction of the inner retina, but on 
occasion transduction of the RPE was observed usually near the ONH. The ONH may represent 
a weak spot in the retina where penetration is easiest. Regardless, the ability to transduce the 
RPE means that virus can reach all the retina layers from IVIT delivery and warrants further 
study to understand IVIT trafficking of rAAV. 
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1.11 Experimental procedures 
 Virus production and purification 
scAAV2 carrying the GFP gene under the control of the ubiquitous CMV promoter were 
provided by the University of North Carolina Vector Core. Briefly, virus was purified by iodixanol 
gradient, ion-exchange chromatography, and dialyzed against 350mM NaCl, 5% sorbitol in 
1xPBS before being aliquoted and frozen at -80C. Viral titer was determined by qPCR against 
wild-type ITR of DNase-resistant vector genomes relative to a virus standard (data not shown).  
 Animal injections 
Adult C57BL/6 mice were used for this study. All animals were housed under 12/12-hour 
light/dark cycle in the University of North Carolina Division of Laboratory Animal Medicine 
facilities and were handled in accordance within the guidelines of the Institutional Animal Care 
and Use Committee at the University of North Carolina. Prior to vector delivery, animals were 
anesthetized with ketamine (75 mg/kg), xylazine (10 mg/kg), acepromazine (1.5 mg/kg), and 
dilated with 1% tropicamide and 2.5% phenylephrine. Proparacaine-HCl was applied to eyes as 
a local anesthetic. Intraocular needles were constructed using 32-gauge cannula connected to a 
Hamilton syringe via tubing filled with water. An air bubble separated the water from the viral 
suspension. Freshly thawed viruses were diluted to working stock and incubated in the 
intraocular needle at room temperature for 10 minutes prior to injection. Needles were 
evacuated and loaded with fresh suspension. Viral suspension was mixed with fluorescein 
sodium salt (Sigma) to confirm successful injection as previously described [48].  
For IS injections, a small entry point was made with the tip of a beveled 30-gauge needle 
in the apex of the cornea. The 32-gauge intraocular needle was gently inserted into the hole and 
then the bevel was turned inward to seal the injection hole. The 1 µl of vector was delivered 
immediately to result in clouding of the cornea. OCT did not provide a clear picture to observe 
stromal separation. For IC injections, 1 µl of vector was delivered through a pilot hole made just 
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off the apex of the cornea. The injection occurred over a period of 30 seconds with just the tip of 
the needle in the anterior chamber and then held in place for 20 seconds for equilibration. For 
IVIT injections, a pilot hole was made with the tip of a beveled 30-gauge needle in the superior 
portion of the eye approximately 0.5 mm posterior to the limbus. The intraocular needle was 
inserted through this hole into the vitreous over the top of the ONH under direct observation 
through the microscope. A volume of 1 µl was delivered at a constant rate over 30 seconds 
using a syringe pump. The needle was pulled back to just the tip and held in place for 20 
seconds to allow for intraocular pressure equilibration before removal. For SR or SC injection, 
the intraocular needle was inserted tangential to the eye and inserted to a depth respective of 
each injection route. Delivery of fluid was immediate and characterized for success by OCT and 
fundoscopy of fluorescein distribution using the Micron IV (Phoenix Research Laboratories). 
Genteal (Novartis) was applied to eyes to prevent corneal drying, and mice could recover on 
heating pads. Fundus imaging was done at six weeks post-injection to observe in vivo GFP 
fluorescence by sedating animals as described above using the Micron IV. 
 Enucleation and histology  
Animals were sedated prior to enucleation. Eyes were placed immediately in formalin 
overnight at room temperature. Next, eyes were placed in 70% ethanol and provided to the 
University of North Carolina Center for Gastrointestinal Biology and Disease Histology Core for 
paraffin embedding and sectioning. Transverse sections were taken from five regions along the 
globe and placed on Superfrost slides (Fisher). Standard antibody labeling for paraffin 
embedded tissue was carried out. Briefly, slides were rehydrated and deparaffinized before 
antigen retrieval was carried out. Slides were blocked and then labeled with primary antibody 
overnight at 4°C. After washing, slides were exposed to secondary antibody. Slides were 
stained for DAPI and coverslipped for imaging. Images were taken on a LeicaSP2 AOBS 
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Upright Laser Scanning Confocal microscope or Olympus IX83 fluorescent microscope using 
cellScen software. Images were manipulated minimally with Adobe Photoshop and Illustrator. 







Figure 1.1 Schematic of AAV entry into the cell 
AAV capsid interacts with receptors (red) on the cell surface for entry into the cell via receptor-
mediated endocytosis. Once in the cell, the acidification of the endosome causes 
conformational changes in the capsid and escape the vesicle. The virus further traffics to 
accumulate on the perinuclear membrane before entering the nucleus. Once in the nucleus, the 




Figure 1.2 AAV genome 
AAV2 genome is a linear, single-stranded DNA and consists of two ORF (rep and cap) 
flanked by the ITRs. The rep gene encodes four non-structural proteins namely Rep78, Rep68, 
Rep52, and Rep40 which are required for viral replication. The p5 internal promoter facilities 
Rep78 and Rep68 transcription while the p19 promoter facilities Rep52 and Rep40 transcription. 
The cap gene encodes three capsid viral proteins- VP1, VP2, and VP3 that constitute the 
capsid. The cap gene is transcribed from the internal p40 promoter. An alternate ORF that 
encoding a protein called assembly activating protein (AAP) is present upstream of the VP3 





Table 1.1 Glycans and co-receptors used by the various AAV serotypes 
 
SIA, sialic acid; HSPG, heparan sulfate proteoglycan; GAL, galactose; FGFR, fibroblast growth 
factor receptor; HGFR, hepatocyte growth factor receptor; LamR, laminin receptor; PDGFR, 






Figure 1.3 Structural analysis of Adeno-associated virus serotype 2 (AAV2) residues 
targeted for modification 
(a) Cartoon representation of the AAV2 VP3 subunit monomer obtained using SWISS-MODEL, 
with regions subject to receptor footprint modifications highlighted in blue. (b) Surface rendering 
of an AAV2 capsid model, with 60 VP3 subunits generated using T = 1 icosahedral symmetry 
coordinates with VIPERdb. Regions subject to receptor footprint modifications are shown in blue 
which also corresponds to the threefold axis of symmetry. The fivefold pore is shown in the 
black circle with the twofold axis of symmetry in black line. (c) Cartoon of AAV2 VP3 subunit 
trimer created on VIPERdb, with modified regions highlighted in blue. (d) Side view of AAV with 
surface modified regions highlighted in blue. Reprinted from Current Opinion in Virology, Vol 18, 
V.J. Madigan and A. Asokan, Engineering AAV receptor footprints for gene therapy, 89-96, 






Figure 1.4 Stereographic Roadmap projections of glycan receptor footprints as viewed 
down the threefold symmetry axis on different naturally occurring AAV serotype capsids 
The threefold symmetry axis is shown in the cartoon inset. Only surface exposed amino acids 
are shown, with each residue boundary depicted in black. The green regions depict the 
protrusion on the threefold surface, while the blue regions represent the surrounding 
depressions. Residues colored in red show the different glycan footprints for (a) AAV2- HS; (b) 
AAV4- MUC; (c) AAV5- SIA; and (d) AAV9-GAL. Reprinted from Current Opinion in Virology, 
Vol 18, V.J. Madigan and A. Asokan, Engineering AAV receptor footprints for gene therapy, 89-






Figure 1.5 Schematic of the eye with a close-up of the posterior segment 
RGC (dark blue), amacrine cells (orange), Muller glia (light blue), bipolar cells (yellow), 
horizontal cells (brown), rods (dark purple), cones (light purple), RPE (teal), choroid (red), sclera 
(white). ILM, inner limiting membrane; GCL; ganglion cell layer; INL, inner nuclear layer; ONL, 




Figure 1.6 Schematic of the mouse eye with routes and close-up of corneal layers 
Various structures of the eye are shown as iris (brown), ciliary body (purple), lens (gray). The 
layers of the posterior eye are displayed with a blood (red) and retinal (blue) layers inside the 
sclera (white). The layers of the cornea are depicted on inset. Epi, epithelium; Endo, 






Figure 1.7 Transduction by IS injection 
(a) Fundus image of the cornea in bright field (left) and GFP filter (right). (b) Ciliary body, (c) 
cornea, and (d) retina histology shows no fluorescence. Epi, epithelium; Endo, endothelium; 
RGC, retinal ganglion cells; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal 





Figure 1.8 Transduction following an IC injection 
Fundus images of (a) cornea or (b) retina in bright field (left) or GFP filter (right). Arrowhead 
indicated GFP-positive RGC axons. (c) Ciliary body, (d) retina, and (e) cornea histology is 
shown with RGC (arrows) and INL (arrowhead) transduction indicated. Scale bar: 50 µm. Epi, 
epithelium; Endo, endothelium; ILM, inner limiting membrane; RGC, retinal ganglion cells; INL, 





Figure 1.9 Transduction of the mouse retina following IVIT injection 
(a) Fundus image of retina in bright field (left) or GFP filter (right). (b) Retinal IHC indicate RGC 
(arrows) and RPE (arrowhead) fluorescence. (c) Retinal IHC show RGC (arrow) and INL 
(arrowhead) transduction. (d) Ciliary body shows no transduction. Scale bar: 50 µm. Epi, 
epithelium; Endo, endothelium; ON, optic nerve; RGC, retinal ganglion cells; INL, inner nuclear 





Figure 1.10 Images of GFP expression after SR transduction 
(a) Fundus image of GFP fluorescence in bright field (left) and GFP filter (right). (b) Ciliary body, 
(c) retina, and (d) cornea histology. Scale bars: 50 µm. Epi, epithelium; Endo, endothelium; 





Figure 1.11 Transduction of mouse retinal following SC injection 
(a) Fundus images shown in bright field (left) and GFP filter (right). (b-c) Retina, (d) RPE, (e) 
ciliary body, and (f) cornea are shown in GFP IHC. Arrows: RGC, Arrowhead: INL. Scale bar: 50 
µm. Epi, epithelium; Endo, endothelium; RGC, retinal ganglion cells; INL, inner nuclear layer; 
ONL, outer nuclear layer; RPE, retinal pigmented epithelium 
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CHAPTER 2: HS binding promotes the accumulation of IVIT-delivered AAV on the retina for 
enhanced transduction but weakly influences tropism 
2.1 Introduction 
IVIT delivery of rAAV vectors has become the preferred route to SR for several reasons, 
including i) technical ease of injection, ii) the potential to deliver vector to a greater area of the 
retina, and iii) less damage to the retina. For clinical applications, IVIT delivery can be 
performed as an outpatient procedure and circumvent the retinal disruption that may exclude 
patients with severe retinal degeneration. However, few serotypes exhibit efficient transduction 
by IVIT delivery [49] which limits its use in the clinic. rAAV2 is one of the few serotypes that 
transduce the RGC by IVIT [49-52]. In rodent models, transduction by rAAV2 has been seen in 
occasional Müller glia, amacrine, and horizontal cells. In addition, rAAV6 expression in the RGC 
and INL has been seen in rodent models [53-55]. The transduction of the other serotypes has 
been minimal, if present at all. Understanding viral trafficking and barriers to efficient IVIT 
transduction provide opportunities to rationally design capsids to overcome the current 
limitations.  
At the vitreoretinal junction, the ILM has been implicated as the barrier responsible for 
the inefficiency of most rAAV vectors to transduce the retina. Despite the limited transduction, 
several AAV serotypes are capable of accumulating at the vitreoretinal junction following IVIT 
delivery [49, 50]. Injections of fluorescently-labeled capsids (rAAV1, 2, 5, 8, and 9) into the 
vitreous of adult rodents showed rAAV2, rAAV8, and rAAV9 accumulated at the ILM, but only 
rAAV2 resulted in transduction [49]. With a degenerated ILM, all five rAAV serotypes were 
capable of transducing the retina [49, 50]. The ILM is composed of the extracellular matrix of the 
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Müller glial end feet which displays an array of glycans similar to other basement membranes  
[56, 57] and may prevent access to cells needed for AAV transduction. The binding of rAAV2, 
rAAV8, and rAAV9 is hypothesized to be due to interaction with the laminin receptor (LamR) at 
the ILM. However, accumulation by LamR alone is insufficient for the transduction of rAAV8 and 
rAAV9. The difference in the three viruses is the HS-binding of rAAV2 and may explain why 
rAAV2 lends to IVIT transduction. Enzymatic digestion of HSPG at the ILM can increase the 
transduction and penetration of rAAV2 in the retina [58]. Therefore, HS-binding on rAAV2 
seems to be both inhibitory and supportive of retinal transduction. rAAV2 shows HSPG-
independent transduction in other tissue [22, 59]. It is possible that rAAV2 does not need HSPG 
binding for retinal transduction and that HSPG may prevent the spread of rAAV2 particles to the 
outer retina. To this end, rAAV2 capsid interactions with HSPG at the ILM may pose the rate-
limiting step to efficient IVIT transduction of the retina. Understanding these interactions will 
guide rational design of vectors for more efficient IVIT transduction.  
To study rAAV interactions at the ILM, a collection of capsids with altered glycan usage 
was used with a scAAV-CBh-GFP cassette for optimized transgene performance. The CBh 
promoter is a shortened form of the CBA promoter with the addition of CMV enhancer elements 
and its small size is beneficial for maximizing the limited transgene capacity of rAAV. The CBh 
promoter has shown exceptional activity in other neuronal tissue compared to CMV or CBA 
promoter activity [60] without potential silencing issues. The scAAV form of the transgene 
facilitates faster expression that is more robust than the classic ssAAV form [33, 61, 62]. In 
addition to optimizing GFP production, ISH was used to track vector following IVIT. Genetic 
capsid mutants were used to understand the role of HS-binding to rAAV transduction of the 
mouse retina without modifying the ILM structure. We used known capsids mutations in the HS-
binding footprint of rAAV2 to carry out this analysis. The motif on the rAAV2 capsid consists of a 
basic patch of residues (R484, R487, K532, R585, and R588) at the base of the threefold axis 
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of symmetry protrusion [59] and capsid mutants like rAAV2i8 replace residues R585Q and 
R588T to ablate HS binding and alter tropism away from HS-rich liver tissue to become more 
systemic when delivered intravenously [22]. Using these capsid mutants, the use of the HS-
binding motif was investigated for rAAV IVIT transduction.  
2.2 Results 
 HS binding on rAAV2 is not required for SR transduction 
A variety of AAV serotypes, both HS-binding and non-HS-binding, work effectively in 
retinal transduction when delivered subretinally, suggesting that HS binding is not needed for 
outer retinal transduction. To determine if rAAV2 requires HS binding in the SR transduction of 
the outer retina, HS-binding was ablated using the rAAV2i8 capsid. Transduction between 
rAAV2 and rAAV2i8 were similar by fundoscopy (Figure 2.1). The strongest signal of GFP 
fluorescence could be seen within the detached area (dotted line), but additional expression 
could be seen outside the bleb area for both vectors. The transduction outside the detachment 
appeared to be RPE. Within the detachment, transduction of multiple layers was observed as 
evident by the fluorescent RGC axons leading to the optic head from the site of injection 
(arrowhead). IHC was used to evaluate the cell tropism between the two vectors (Figure 2.1b). 
The RPE and ONL were the major cell layers transduced by both vectors. Areas could be seen 
where high RPE transduction but low ONL transduction occurred, indicating that RPE is the 
predominant cell type to be transduced. Transduction of the ONL occurred predominately in 
rods for both rAAV2 and rAAV2i8 capsids (Figure 2.2a). Similar to the transduction of rAAV2, 
rAAV2i8 transduction of cells in the INL were identified as rod bipolar cells and Müller glia 
(arrowhead, Figure 2.2b, c). These results confirm that the rAAV2i8 capsid is infectious in retinal 
tissue by SR delivery. 
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  HS binding of rAAV2 is required for IVIT transduction in mice 
Then HS-binding was assessed for IVIT transduction of rAAV2. Both rAAV2 and 
rAAV2i8 capsids were delivered intravitreally to adult mice at 108 vg.  rAAV2-injected eyes were 
fluorescent at the first imaging time point of two weeks whereas rAAV2i8 showed no expression 
(data not shown). Eyes were evaluated for up to twelve weeks for the possibility of slower 
expression kinetics. During that time, rAAV2 fluorescence continued to increase, but no 
fluorescence was detected with rAAV2i8. By twelve weeks, rAAV2 capsid leads to a diffuse 
pattern of fluorescence over the neural retina as seen by fundus imaging (Figure 2.3). This 
diffuse pattern can be explained by the HSPG staining along the entire inner retinal surface 
(Figure 2.4). The rAAV2i8 capsid did not yield observable GFP fluorescence by fundoscopy 
which resulted in a 300-fold reduction in GFP fluorescence. We tried a higher titer of 2x 109 vg 
for both rAAV2 and its HS-binding mutant to maximize the chance to observe expression 
(Figure 2.5). Of course, the expression was much greater with higher titered rAAV2 virus 
compared to what was observed with the lower titer-injected eyes. To confirm that the vitreous 
did not specifically inhibit the transduction capsid, virus was mixed with vitreous and delivered 
subretinally. Both rAAV2 and rAAV2i8 shared intense expression throughout most of the retina 
(Figure 2.6) that was similar to no vitreous controls. 
The eyes injected intravitreally with low titer rAAV were further evaluated by IHC and 
FISH. rAAV2 transduction was detected in the RGC and INL, with some transduction of 
photoreceptors observed (arrow, Figure 2.3b). The IHC of HS-ablated rAAV2 capsids revealed 
a lack of transduction except for few GFP-positive rods. This phenotype has several 
mechanisms which could be responsible to this phenotype, including changes in the tropism or 
distribution of the rAAV2i8 capsid. Further analysis using FISH determined the distribution of 
transgenes following IVIT delivery. This is a better alternative to IHC using antibodies against 
the capsid have dissociated to release the transgene. Similar to the IHC expression, FISH 
33 
 
signal for rAAV2-delivered transgenes was detected in the RGC and INL (Figure 2.3c). rAAV2i8-
injected eyes showed few transgenes present in the ONL, but no signal was detected in either 
the RGC or INL. These transgenes most likely represent episomes that are stable in the retina. 
These few transgenes in the ONL may represent a HS-independent way for rAAV2 to enter the 
retina. 
 HS binding is necessary for the vitreal accumulation of rAAV2 at the ILM in mice 
To obtain a better understand of the trafficking differences between the rAAV2 capsid 
and its HS-binding mutants following IVIT delivery, eyes were enucleated soon after injection for 
FISH analysis. FISH was used as an alternative to modifying the capsid with fluorescent 
particles for visualizing the trafficking. Previous reports have shown AAV particles accumulate at 
the ILM 24 hours post-injection [49] which was confirmed using our FISH protocol and indicated 
the detection of transgenes carried in capsids that may still be intact (data not shown). The time 
point was extended to three days post-injection to allow sufficient time for trafficking differences. 
A range of vector amount was used to capture any concentration effect in accumulation. In 
addition, the enzymatic time for FISH signal detection was shortened to provide a more dynamic 
range. PBS-injected eyes served as the negative control which had minimal background 
labeling (Figure 2.7). With the shortened detection time, a dose of 1x108 vg had only weak 
signal in retinas for both rAAV2 and HS-deficient rAAV2-R585E capsids. At a dose of 5x108 vg, 
transgenes delivered by rAAV2 showed an accumulation at the ILM (black arrow), as well as 
being present in the ONL (arrowhead). Without HS binding, rAAV2-R585E had only minimal 
signal in the ONL. At the highest dose tested of 2x109 vg, rAAV2 resulted in even greater signal 
intensity at the ILM (black arrow) showing increased accumulation of the vector. Additional 
aggregation of transgenes was seen in the ONL (arrowhead). At the same dose, few rAAV2-
R585E-delivered transgenes were detected in the ONL of the retina (arrowhead) but did not 
result in any accumulation at the ILM. Taken together, these results indicate i) that HS binding 
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on rAAV2 helps to accumulate vectors at the ILM, ii) that this accumulation increases the 
number of transgenes residing in the retina, and iii) that capsids can penetrate the retina from 
the vitreous without binding to HS but to a far less extent (Figure 2.8). Once capsids pass 
through the ILM barrier, they seem capable of trafficking rapidly to the outer retina. This 
highlights that rAAV’s rate-limiting step to efficient intravitreal transduction of the retina lies with 
the interaction between capsid and ILM, and enhancing this bottleneck step of trafficking will 
likely impact transduction in the retina. 
 HS binding is necessary for the vitreal accumulation of rAAV2 in human retinas 
The abundant HSPG staining at the ILM in many animal models, including humans 
(Figure 2.9), suggests this mechanism may translate across species for clinical applications. To 
evaluate this hypothesis, a viral binding assay was done on human retinas ex vivo and 
quantified by qPCR. Vectors were applied into the vitreous a couple of hours before being 
harvested. Transgenes carried by rAAV2 were bound to the retina, unlike those of the rAAV2i8 
capsid (Figure 2.10). The HS-deficient rAAV2i8 had relatively low vector binding in any of the 
collected tissue, but did show a significant increase in binding to the choroid and sclera 
compared to rAAV2. Together with the mouse data, these results corroborate the mechanism 
that HS binding promotes the accumulation of AAV vector out of the vitreous and onto the ILM 
for greater retinal penetration and transduction. 
 HS binding increases the IVIT transduction of other AAV serotypes 
Other serotypes may benefit from the addition of the HS-binding motif and add to the 
diversity of vectors that could be used for IVIT transduction. The rAAV1 and rAAV6 serotypes 
differ by only six amino acids, with a single residue responsible for their difference in HSPG 
binding [19, 63].  To evaluate the influence of HS-binding between rAAV1 and rAAV6 retinal 
transduction for IVIT transduction, the single residue mutant capsids were tested intravitreally in 
mice. Although rAAV1 and the HS binding rAAV1-E531K had similar patterns of expression, 
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rAAV1-E531K had 3-fold greater GFP fluorescence compared to rAAV1 (Figure 2.11a). The 
removal of HS-binding in rAAV6 using the rAAV6-K531E capsid lead to a reduction in retinal 
fluorescence by fundoscopy (Figure 2.12). Both rAAV1 and rAAV6 capsids displayed a punctate 
expression pattern that clustered around the retinal vessels and has been documented in other 
reports [53, 54]. Because of the homology between rAAV1 and rAAV6, only rAAV1 and rAAV1-
E531K were further evaluated for possible differences in cell tropism. IHC performed on these 
retinas showed the transduction of mainly Müller glia for both capsids by the co-localization of 
GFP and glutamine synthetase (arrowhead, Figure 2.11b). Additional cells of the INL appear to 
be transduced (arrow). Both rAAV1 and rAAV1-E531K showed transduction of a few RGC and 
photoreceptors. The similar transduction patterns of rAAV1 and rAAV1-E531K indicated that 
HS-binding does not alter the tropism of rAAV1. To confirm that rAAV1-E531K does not use 
HSPG for transduction, soluble heparin was mixed with capsids and applied to cells for an in 
vitro competition assay. rAAV2 requires HSPG for in vitro transduction [18] and showed a dose 
dependent decrease in transduction (Figure 2.13). Neither rAAV1 nor rAAV1-E531K 
transduction were affected at any heparin dose, indicating that the rAAV1-E531K capsid does 
not depend on HS binding for transduction. Transduction with rAAV1-E531K lead to fewer GFP-
positive cells compared to rAAV1, indicating that the single amino acid change alone does not 
provide an enhancement in transduction.  
In the same manuscript outlining the amino acid involved in rAAV1/rAAV6 transduction, 
a single amino acid mutant was identified on rAAV8 which provided HS-binding capability 
rAAV8-E533K [19]. At eight weeks post-IVIT administration, fundus images revealed low GFP 
fluorescence for rAAV8 with slightly higher GFP fluorescence that was hazy with rAAV8-E533K 
(Figure 2.14). FISH analysis to observe trafficking differences soon after injection and found HS-
binding promoted the accumulation of vector at the ILM and within the retina (Figure 2.15). 
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These results suggest that HS binding alone is sufficient to enhance the transduction of IVIT-
delivered AAV capsids by increasing the amount of vector that accumulate onto the retina. 
 Motif of rAAV1 lead to transduction along retinal vessels in mouse retinas 
One way to design for new capsid variants is to build from a known serotype by adding 
mutations or motifs. This is the method used when adding the HS-binding motif to the various 
rAAV capsids. The addition of the HS-binding motif helped to increase the vector accumulation 
on the retina, but did not alter the transduction pattern of rAAV1 indicating other capsid motifs 
are responsible for tropism. To determine if a capsid motif from rAAV1 could influence the 
transduction of rAAV2, the previously described chimeric rAAV2.5 capsid [64] was used for IVIT 
transduction. While distinct from either parental serotype, the rAAV2.5 capsid revealed an 
expression pattern surrounding the retinal vessels (Figure 2.16). IHC of these eyes did not 
reveal any major tropism differences compared to rAAV2, in that RGC, Müller glia, and other 
cells of the INL were transduced by the chimeric rAAV2.5 capsid but some eyes showed a 
skewing of transduction to Müller glia. A more recent paper has shown that the amino acid at 
position 265 on the rAAV2.5 capsid to be solely responsible [65]. Therefore, a rAAV2-265D 
point mutant was tested IVIT and revealed similar expression to the rAAV2.5 parent (Figure 
2.17). 
 rAAV2.5 testing in large animal models 
To determine if the rAAV2.5 was conserved across animal models, CBh-GFP vector was 
IVIT-delivered to rabbits. Both rAAV2 and 2.5 transduced the vessels, but only rAAV2.5 
transduction was specific to the vessels (Figure 2.18). rAAV2.5 was further tested in non-human 
primate (NHP) by both SR and IVIT deliveries (Figure 2.19). Intense SR transduction resulted in 
the transduction of PRs whereas IVIT transduction was minimal and restricted to the fovea 
(Figure 2.20). To determine if inhibitory factors were responsible for the lack of IVIT 
transduction, ocular fluid samples were collected pre- and post-injection were mixed with virus 
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or applied to cell culture alone. No inhibition of transduction was seen with any fluid (Figure 
2.21). Surprisingly, the post-injection vitreal fluid had rAAV2.5 infectious particles as noted by 
the GFP-positive cells when vitreous only was delivered as a negative control. To assess if any 
rAAV2.5 vector made it to the retina, ISH was carried out on SR and IVIT injected retinas. SR 
shows transgenes in the ONL while IVIT transgenes were only at the ILM (Figure 2.22).  
 Motif from rAAV9 lead to transduction of Muller glia in mouse retinas 
An additional chimeric rAAV2 capsid, rAAV2G9, has been shown to use HS and GAL 
binding interchangeably for cell transduction [66] since each motif is non-overlapping (Figure 
2.23). The rAAV2G9 vector has been tested for transduction within the brain by two routes of 
injections [67] and further highlights the importance of injection site to the transduction of CNS 
cells. The dual glycan vector remained in the CNS rather than disseminating to peripheral 
tissues [67]. Although the IVIT and SR injections remain confined to the eye, this dual glycan 
has never been tested in the eye and therefore could yield a vector with preferable transgene 
expression. The use of rAAV2G9 by IVIT delivery resulted in a punctate expression across the 
retina, which correlated to specific transduction of Müller glia (Figure 2.24). The galactose motif 
was structured from the rAAV9 capsid so both rAAV9 and a HS-ablated rAAV2i8G9 capsids 
were tested, but showed no expression following IVIT delivery (Figure 2.25). This indicated that 
galactose binding alone was insufficient to lead to transduction within the retina. Lectin antibody 
to identify the presence of galactose in the retina indicated much of the staining occurred 
around the ONL but was not very abundantly expressed (Figure 2.26). 
 Combination of motifs in the rAAV2.5G9 can result in enhanced, targeted 
transduction 
To determine which motif was dominant, a double chimera rAAV2.5G9 was created and 
tested. The intravitreal delivery of rAAV2.5G9 lead to expression similar to the rAAV2.5 parent 
when imaged by fundoscopy (Figure 2.27). Quantification of the expression comparing all 
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capsids showed rAAV2.5 and rAAV2.5G9 to have the highest transduction and non-HS-binding 
capsids to have the lowest transduction (Figure 2.28). The fluorescence around the retinal 
vessels was very evident with punctate expression found around the vessels. IHC of the 
rAAV2.5G9-injected eyes revealed a Müller glia specific transduction profile (Figure 2.27). 
Therefore, the addition of either the rAAV1 or rAAV9 motif appear to have equal ability to control 
tropism, but dominate over the tropism provided by the HS-binding motif. 
2.3 Discussion 
The experiments conducted herein provide a greater understand for the early trafficking 
of rAAV following intravitreal delivery and how to exploit this trafficking to enhance transduction. 
As virus is injected into the vitreous, it travels through the vitreous humor, resulting in a dilution 
of the vector concentration. Once the virus reaches the retina, the capsid interacts with the 
glycans present on the ILM to concentrate the virus out of the vitreous. Days following delivery. 
After concentration of the virus, vectors penetrate through the retinal layers where they 
transduce the various retinal cells. In the weeks after delivery, transgene expression is 
detectable and remains so for months. Not all AAV serotypes aggregate sufficiently to promote 
penetration into the retina and lead to transgene expression. This issue can be circumvented 
through the application of HS-binding motif on the capsid, thereby allowing the capsid to interact 
with the ILM, without causing a change a tropism.  The interaction of rAAV capsids with the 
ILM poses the rate-limiting step to retinal trafficking [49, 50]. Therefore, interaction with this 
membrane should be increased to maximize the number of capsids entering the retina. Pores 
present in the ILM may explain why few HS-binding deficient capsids could pass through the 
ILM and traffic rapidly to the outer retina. Relatively similar amount of rAAV2 capsids were found 
rapidly in the outer retina, supporting the idea of a non-glycan-mediated entry like through a 
pore. These deep-penetrating vectors may represent the few capsids whose trajectory was align 
to allow them to quickly pass through the pores and through the retinal interior. However, most 
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vectors must interact with the ILM before they can penetrate the retina. If capsids cannot 
interact with the ILM, they remained diluted in the vitreous, unable to transduce the retina. Even 
if a higher concentration of vector is used, lack of interaction with the ILM is insufficient to 
aggregate capsids onto the retina surface and lead to further retinal transduction. We could 
increase the amount of vector in the retina by adding a HS-binding motif to the non-HS-binding 
capsids. This may be an alternative strategy to current methods of getting high titer vector into 
the retina using to either ILM digestion or a sub-ILM injection [49-51, 68]. It is easy to see how 
development of better capsids that are capable of transducing without these invasive aides 
would be of interest for researchers and clinicians alike. 
The ILM structure is found across multiple species and could serve to attract and 
concentrate rAAV capsids out of the vitreous for not just mice, but also human. As 
hypothesized, we found the same accumulation on the retina with only the HS-binding rAAV2 
using human ex vivo retinas. The kinetics of vector dispersion through the vitreous humor are 
likely to be slower due to the volume, which will also mean longer times until interaction with the 
ILM and penetration into the retina. Although these kinetic studies must be worked out further 
for primate intravitreal delivery, the mechanism that HS-binding motifs positively influence vector 
accumulation on the retina will make vectors more effective. It is important to remember that the 
transduction observed in a mouse model may not be indicative to other animal models. While 
the mouse has become a standard model for retinal gene transfer, certain size and anatomical 
differences exist between them and larger animal models. In addition, the thickness differences 
of the ILM between mouse and primates may lead to selection of capsids that are not as 
efficient across species. The addition of the HS-binding motif, mechanism of vector 
accumulation was conserve in both mouse and human retinas. The phenotype of rAAV2.5 was 
confirmed in a rabbit model and validates translation of this work. 
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The interaction between the AAV capsid and HS binding is mediated by a static charge. 
The negative charge of the sulfate groups on the heparan chain, which are found on the 
proteoglycan core of HSPG, serves to attract the basic patch of residues on the rAAV2 capsid. 
Through this sulfate interaction, the heparin chain falls along the inner surface of the 3-fold 
protrusion of the capsid surface. We used capsid mutants to change this charge interaction to 
no longer attract the sulfate group and obstructs the heparan chain interaction with the capsid. It 
could be argued that this charge interaction is the most important interaction between rAAV and 
ILM; therefore, the capsid is really drawn to any highly-charged molecule. We used dextran 
sulfate to act as a surrogate for heparan sulfate. We mixed rAAV2 capsids with dextran sulfate 
or heparan sulfate (heparin) or un-sulfated heparan sulfate (heparosan) before IVit delivery. We 
found heparin and heparosan dramatically decreased transduction of rAAV2 while dextran 
sulfate resulted in no change (Figure 2.29). This data indicates that rAAV2 specifically interacts 
with HSPG and not through electrostatic charge alone.  Therefore, random changes to make the 
capsid more charged may have little influence.  
Indeed, HS binding lead to a greater presence of transgenes in the retina compared to 
the parent capsid when assessed by FISH soon after injection. Transgenes of non-HS-binding 
rAAV1 and rAAV8 could still be detected in the retina, but to a lesser extent. The lack of 
expression with HS-binding rAAV3 when injected intravitreally (data not shown) was expected 
because this serotype is inefficient in the transduction of most cell types [69] and may encounter 
additional barriers for efficient transduction of cells. rAAV6 is a serotype of interest for retinal 
transduction and has been modified to increase the specific transduction of Müller glia using the 
ShH10 capsid [70]. Without HS binding, the ShH10 vector may reveal a much weaker 
fluorescence. From our model, any capsid that had an HS-binding motif would can accumulate 
at the ILM. The recent publication by Boye et al. used HSPG-binding rAAV5 and rAAV8 but was 
unsuccessful to enhance their GFP fluorescence, indicating this HS-binding enhancement is not 
41 
 
universal to all capsids [71]. This may be related to their shortened CBA promoter and that use 
of a different promoter may revealed expression. We would predict that rAAV5 capsid should 
have enhanced transduction with the HSPG binding mutation. In addition, other labs have 
tested rAAV5 and rAAV8 using a CAG promoter and have shown expression [72] and serves as 
reason to reevaluate all rAAV capsids transduction following intravitreal delivery by FISH. By 
using GFP expression as the only way of analyzing where capsids have trafficked in the retina, 
there is an incomplete picture formed by the activity of the promoter. FISH analysis provides a 
simple way to detect the location of viral transgenes as a surrogate for the location of capsids. 
FISH is better alternative to modifying the capsid surface with fluorescent Cy3 dye which binds 
to the Lys residues on the capsid. Modifying residues on the rAAV1 capsid can alter expression 
levels (i.e. rAAV1-E531K vs rAAV1), so it could be argued that the Cy dye could be masking the 
expression of serotypes in earlier studies [49, 50]. 
Increasing the viral concentration could increase the vector interaction with ILM and in 
the retina, but is more likely to evoke an immune response as the vitreal space is not immune 
privileged like the subretinal space [73]. Therefore, it is optimal to use lower concentrations of 
vector to avoid this response. Therefore, we chose to work with a low concentration of vector 
was used to maximize expression rather than using high titers of vector. Other labs sought to 
maximize expression in other ways. A recent manuscript lead to a selection of a peptide 
incorporated onto the rAAV2 capsid has enhanced IVIT transduction in both mouse and non-
human primates [74]. While this peptide is located near the HS binding footprint, this capsid 
shows a dependency on HSPG for transduction and may still exploit the same HS-mediated 
accumulation mechanism outlined above. This hypothesis was tested using the peptide in the 
context of HS binding. As predicted with our model, GFP expression was only detected when 
the Arg (R) residues involved in the HS-binding motif were present (Figure 2.30). We found the 
peptide insertion to reduce rAAV2 transduction, suggesting that a reduction in HSPG binding 
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may be met with a reduction in IVIT transduction. Other attempts to enhance transduction use 
capsids modified to avoid proteasomal degradation [75], thereby enhancing intracellular 
trafficking to help increase the transgene expression of intravitreally-delivered capsids. 
However, a recent publication suggests that these vectors may not benefit from late-stage traffic 
enhancement [71] that are downstream of ILM binding. To take advantage of the retinal 
structure, binding to the ILM can be used to accumulate vectors at the retina for transduction.  
Although HSPG is abundant at the ILM, other receptors can play a role in the 
transduction of the retina from the vitreous. The transduction by rAAV1 and rAAV6 suggest the 
presence of 2,3 and 2,6 N-linked SIA at the ILM. The pattern of transduction observed by 
fundus may indicate a distinct pattern of sialic acid in the retina that is visible by flat mount 
staining. It would be beneficial to perform FISH on whole mount retinas soon after injection to 
observe accumulation of vector. Laminin receptor (LamR) is known to interact with rAAV2, 
rAAV3, rAAV8, and rAAV9 serotypes [24] and laminin staining is at the ILM restricted to the 
blood vessels. Although these capsids can interact with laminin receptors at the vitreoretinal 
junction, this interaction seems insufficient to promote efficient intravitreal retinal transduction. 
Again, a re-evaluation of all rAAV serotypes using FISH as the detection method would provide 
a greater understanding to virus trafficking and transduction in the retina. 
The similar transduction profiles of SR-delivered rAAV2 and rAAV2i8 indicate that rAAV2 
does not require HS binding for retinal transduction. It may be that the SR delivery effectively 
concentrates the vector, thereby skewing capsids towards expression. In addition to 
transduction by receptor-mediated endocytosis, SR provides abundant rAAV vectors to the 
phagocytic RPE and may explain why the RPE appears to be the primary cell target by both 
rAAV2 and rAAV2i8. It would be of interest to see if the RGC transduction of subretinally-
delivered rAAV2 is due to the HSPG on the ILM pulling on the vector. FISH could be used to 
map the trafficking of SR-delivered vector to better understand this phenomenon. 
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Amino acids transplanted from AAV1 capsid onto AAV2 capsid were sufficient to alter 
the transduction pattern to mimic the pattern closer to that observed with AAV1. It is unclear 
how the difference in residues between rAAV2 and rAAV2.5 promote this vascular tropism. The 
rAAV2.5 capsid has been shown to bind HS with the same efficiency as rAAV2[64] and no 
evidence of additional cellular receptor usage has been identified. The transduction of the retina 
along the vasculature with rAAV2.5 may be a result of the tropism shift towards Muller glia. 
Muller glia are known to wrap around the vasculature in the retina and may account for this 
phenotype. However, the transduction shift to favor Muller glia may indicate the addition of a 
receptor used by rAAV2.5 that is found on the Muller glia cells. Although transduction of the 
vasculature endothelial cells has been previously shown with rAAV2.5 after cardiac injection 
[76], histology of rAAV2.5-injected retinas did not reveal co-localization of GFP and an 
endothelial cell marker (data not shown). The use of the rAAV2.5 capsid also displayed greater 
fluorescence than the rAAV2 capsid. The higher transduction by rAAV2.5 has been shown in 
multiple tissues, including brain[60] and muscle[64]. Similar to previously published results, the 
phenotype of rAAV2.5 in the eye could be recapitulated by a single point mutant at position 265.  
Finally, galactose binding alone was insufficient to transduce the retina, but in conjunction 
with HS binding provided a tropism shift to specific transduction of Müller glia. The results of the 
immunostaining did not provide a clear mechanism to the Muller glial tropism of rAAV2G9. 
Galactose was detected only in the outer retina. If capsids are modified to enhancement of 
intracellular trafficking, rAAV8 and rAAV9 capsids result in GFP expression in retinas with 
normal ILM [77]. This suggests capsids can penetrate the retina, but face additional intracellular 
barriers to efficient transduction. 
To ensure that the phenotype observed with rAAV2.5G9 was reproducible, rAAV2- and 
rAAV2.5G9-CBh-GFP vectors were provided independently to two established retinal gene 
therapy labs (Drs. Robin Ali and Alberto Aurrichio) to perform intraocular injections. All injections 
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resulted in the fluorescence pattern described above and the similar tropism for Muller glia (data 
not shown). Increase in fluorescence could be observed with increased doses of vector. 
As more of the capsid biology of AAV becomes available, we will have better insight into 
which capsid motifs can be modified to produce a desired outcome. Taken together, the 
collection of capsids show that HS binding is beneficial to vector transduction, but that other 
capsid motifs have a greater influence on the transduction profile of the capsid in the retina. 
These capsid motifs are important for the targeting of vectors to specific cells of the retina and 
capsid motifs can enhance the transduction levels of currently available vectors with few capsid 
changes needed. While retinal gene therapy has been met with success in the past, long-term 
data is beginning to reveal that treatment of patients is more complicated than previously 
thought. The disappointing results of AVA-101 trial for wet AMD and the weakening therapeutic 
response seen in LCA patients indicate that there are additional mechanisms that must be 
understood to effectively treat patients. It may be that current therapies only work to delay the 
pathology, but do not work to reverse the damage already done by the time the patient seeks 
help. If this is the case, early intervention in the treatment of retinal degenerative diseases will 
yield the greatest therapeutic response. While most of the patients enrolled in retinal gene 
therapy trials are adults, some children have been enrolled and could provide evidence to 
support the use of early intervention. 
2.4 Experimental procedures 
 Virus production and purification 
scAAV carrying the GFP gene under the control of the ubiquitous CBh promoter [78] 
were produced by triple transfection method using polyethylenimine [25]. Viruses were 
harvested as previously described [66]. Lysate was clarified by centrifugation at 6200xg and 
purified by iodixanol gradient ultracentrifugation at 402,000xg for 1 hour. Viruses were pulled 
from the 40%/60% interface, purified by ion-exchange chromatography on a 1-ml Q HyperD F 
45 
 
column (Pall) and eluted with 200 mM NaCl, 25 mM Tris [pH 9.0]. AAV8-E533K vector was 
difficult to produce a significant yield by iodixanol. Therefore, AAV8 and AAV8-E533K were 
purified by CsCl and then by sucrose to obtain pure vector. Viruses were dialyzed against 
350mM NaCl, 5% sorbitol in 1xPBS before being aliquoted and frozen at -80C. Viral titer was 
determined by qPCR against wild-type ITR of DNase-resistant vector genomes relative to a 
virus standard (data not shown). Viruses underwent electrophoresis on a 1% Bis-Tris gel 
(Novex) and silver stain (Life Technologies) to assess purity (data not shown).  
 Animal injections 
Adult C57BL/6 mice were used for this study. All animals were housed under 12/12-hour 
light/dark cycle in the University of North Carolina Division of Laboratory Animal Medicine 
facilities and were handled in accordance within the guidelines of the Institutional Animal Care 
and Use Committee at the University of North Carolina. Prior to vector delivery, animals were 
anesthetized with ketamine (75 mg/kg), xylazine (10 mg/kg), acepromazine (1.5 mg/kg), and 
dilated with 1% tropicamide and 2.5% phenylephrine. Proparacaine-HCl was applied to eyes as 
a local anesthetic. Intraocular needles were constructed using 32-gauge cannula connected to a 
Hamilton syringe via tubing filled with water. An air bubble separated the water from the viral 
suspension. Freshly thawed viruses were diluted to working stock and incubated in the 
intraocular needle at room temperature for 10 minutes prior to injection. Needles were 
evacuated and loaded with fresh suspension. Viral suspension was mixed with fluorescein 
sodium salt (Sigma) to confirm successful injection as previously described [48]. All injections 
were carried out by the same surgeon. For IVIT injections, a pilot hole was made with the tip of 
a beveled 30-gauge needle in the superior portion of the eye approximately 0.5 mm posterior to 
the limbus. The intraocular needle was inserted through this hole into the vitreous under direct 
observation through the microscope. A volume of 1 µl as delivered at a constant rate over 30 
seconds using a syringe pump. The needle was held in place for 20 seconds to allow for 
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intraocular pressure equilibration before removal. For SR injection, the intraocular needle was 
inserted tangential to the eye. Delivery of fluid was immediate and characterized for success by 
OCT and fundoscopy of fluorescein distribution using the Micron IV (Phoenix Research 
Laboratories). Genteal (Novartis) was applied to eyes to prevent corneal drying, and mice could 
recover on heating pads. 
 In vivo imaging 
Fundus images and OCT were carried out by dilating and sedating animals as described 
above. All fluorescent images were taken under the same settings and similar retinal position 
using the Micron IV. The green channel of the fluorescent fundus image was isolated, converted 
to grayscale, and quantified by integrated density measurements using ImageJ (National 
Institutes of Health). 
 Enucleation and histology 
Animals were sedated and perfused with PBS containing 1 unit heparin per ml, followed 
by 4% PFA in PBS. Eyes were enucleated and a puncture was made anterior to the limbus 
using an 18G needle before incubating in 4% PFA for 10 minutes. The anterior segment, 
musculature, and lens were removed and eyecups were placed in 10% sucrose at 4C 
overnight followed by 20% and 30% sucrose incubations. Eyecups were embedded in OCT 
cutting media (Sakura), frozen at -20C, and stored at -80C. Ten-micron transverse sections 
were collected on pre-cleaned Superfrost Plus slides (Fisher) and stored at -80C until further 
processing.  
 IHC of retinal sections  
Sections were washed in TBS containing 0.3% Tween-20 (TBS-T) and incubated in 
blocking buffer (10% normal goat serum, 0.1% Triton-x 100 in PBS) for 1 hour in a humid 
chamber. Slides were incubated in antibody solution (3% NGS, 0.1% Triton x-100 in PBS) with 
primary antibodies in a humid chamber overnight at room temperature. Primary antibodies used 
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were rabbit anti-GFP (1:500; Millipore), mouse anti-glutamine synthetase (1:100; Abcam), 
mouse anti-heparan sulfate 10E4 epitope (1:70; Amsbio), mouse anti-rhodopsin (1:100; 
Rockland), and mouse anti-PKC alpha [H-7] (1:250; Santa Cruz). After three washes with TBS-
T, secondary fluorescent antibodies were applied in antibody solution for 2 hours in a humid 
chamber. Secondary antibodies were Alexa-Fluor 488 goat anti-rabbit (1:1000; Molecular 
Probes), Alexa-Fluor 568 goat anti-mouse (1:1000; Molecular Probes), or Alexa Fluor 568 rabbit 
anti-goat (1:1000; Molecular Probes). Slides were mounted in Prolong Gold Antifade with DAPI 
(Molecular Probes) as stated by manufacturer’s protocol. Images were taken on a LeicaSP2 
AOBS Upright Laser Scanning Confocal microscope or Olympus IX83 fluorescent microscope 
using cellScen software. Images were manipulated minimally with Adobe Photoshop and 
Illustrator. 
 Soluble HS analog assay 
For in vitro studies, HEK293 cells were plated in a 24-well dish at a density of 105 cells 
per well and allowed to adhere overnight at 37C, 5% CO2. Viruses were pre-incubated with 
soluble heparin at the specified concentrations for 1 hour prior to the addition to cells at a 
concentration of 10,000 vg per cell. Cells were harvested 48 hours later and quantified by flow 
cytometry. 
 Fluorescence in situ hybridization 
The GFP gene was cloned into the pSPT18 vector (Roche RNA in vitro transcription kit) 
at the HindIII and EcoRI sites and sequenced for confirmation. Plasmids were linearized with 
these restriction enzymes and purified by phenol-chloroform extraction/ethanol precipitation and 
re-suspended in water. Linearized plasmids were quantified by spectrophometry and verified by 
DNA sequencing before in vitro transcription of antisense and sense riboprobes were carried as 
described by the manufacturer (Roche). Aliquots of riboprobes were frozen in water and were 
quantified as described by the manufacturer and analyzed by gel electrophoresis and SYBR 
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Gold staining (Invitrogen). Riboprobe functionality was assayed for sensitivity and selectivity by 
dot blot of virus controls to a positively-charged nitrocellulose membrane (Roche). Both sense 
and antisense probe could detect viral GFP transgene equally (data not shown).  
Frozen slides were heated to 55C for 10 minutes and pre-treated as previously 
described [79]. Slides were then incubated in hybridization buffer (50% formamide, 10 mM Tris 
[pH 7.6], 200 g/ml yeast tRNA, 1x Denhardt's solution, 10% dextran sulfate, 600mM NaCl, 
0.25% SDS, 1mM EDTA [pH 8]) without probe at hybridization temperature of 65C for 2 to 4 
hours. Slides were transferred to pre-hybridization buffer containing 50 ng/ml of sense riboprobe 
to specifically detect DNA and not mRNA transcripts. Slides were heated to 80C for 20 
minutes, snap chilled on ice, and incubated overnight at 65C. Slides were washed in 50% 
formamide/2x SSC at 65C for 30 minutes, 2x SSC at 55C for 20 minutes, and two washes of 
0.2x SSC at 55C for 20 minutes. Slides were washed in 1x Washing Buffer (Roche) followed by 
incubation of 10% sheep serum in 1x Blocking Buffer for 1 hour in a humid chamber. Sheep 
anti-DIG-AP antibody (1:1000; Roche) was applied and incubated 2 to 3 hours in a humid 
chamber. Slides were washed three times in Washing Buffer with gentle agitation for 10 minutes 
followed by two incubations in Detection Buffer (100 mM Tris, 100 mM NaCl, 10 mM MgCl2 [pH 
8.0]) for 10 minutes. HNPP/Fast Red detection substrate was prepared and applied as directed 
by the manufacturer (Roche) for two to three applications. Following the detection reaction, 
slides were rinsed in distilled water and coverslipped using Prolong Gold antifade reagent with 
DAPI. Images were taken on a LeicaSP2 AOBS Upright Laser Scanning Confocal microscope 
or an Olympus IX83 fluorescent microscope.  
 Ex vivo human retinal binding assay 
Human whole globes were procured immediately after death and placed in a moist 
chamber on ice for 4 days. The anterior chamber, iris, and lens were removed and the globe 
was quartered with some vitreous remaining attached to the retina. Ten l of vector was applied 
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to the vitreous at a titer of 2x109 vg/l and allowed to bind to the retina for 2 hours at 4C. The 
quartered retinas were kept out of media to prevent the vector solution from spilling over the 
sides of the retinal slice. Following the incubation, PBS was washed over the tissue, collected, 
and stored at -80C. Vitreous, retina, choroid, and sclera were collected separately and stored 
at -80C. Tissue samples were digested and purified using the DNeasy Blood & Tissue kit 
(Qiagen). Virus in the collected samples was quantified by qPCR using primers against GFP 
and hGAPDH housekeeping genes. 
 NHP injections 
Two female cynomolgus primates (age: #313- ~3.5 years, #309- ~1.5 years) were 
housed at the University of Pennsylvania. Primates were tested for neutralizing antibodies to 
rAAV2 prior to injection. A total of 1E11 vg scAAV2.5-CBh-GFP were delivered in 150 µl volume 
either SR or IVIT, imaged one month later, and sacrifice at 2 month timepoint. Injection 
assessment, in vivo fundus imaging, histology and IHC were provided by Dr. Jean Bennett. ISH 






Figure 2.1 GFP fluorescence following subretinal delivery of rAAV2 and HS-deficient 
rAAV2i8 vector eight weeks post-injection 
(a) Images show representative fundus and fluorescence of eyes treated with rAAV2i8 capsid 
and rAAV2 capsid. Dotted lines indicated detached area of injection. Transduction of ganglion 
cells can be observed by the GFP axons leading from the injection site to the optic disc in 
rAAV2-injected eyes (arrowhead). (b) Histology of eyes indicated similar transduction of RPE 
and ONL between the rAAV2 and its HS deficient rAAV2i8 vector. Scale bar = 20 m. RGC, 





Figure 2.2 IHC of subretinally injected rAAV2i8 and rAAV2 capsids 
Both capsids showed most transduction in the ONL and RPE, with fewer transduced cells of the 
INL and RGC. Staining for rhodopsin indicated that transduction occurred in rods for both rAAV2 
and rAAV2i8 capsids. Transduction of rAAV2i8 lead to transduction of (b) rod bipolar cells and 
(c) Muller glia. Scale bar = 50 um. RGC, retinal ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer.  
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Figure 2.3 GFP fluorescence following intravitreal delivery of rAAV2 vector and its HS-
binding deficient variants twelve weeks post-injection 
(a) Images show representative fundus and fluorescence of eyes treated with rAAV2 capsid or 
rAAV2i8 capsid. Quantification of fundus images showed a 300-fold decrease in expression 
between rAAV2 and rAAV2i8. (b) IHC of rAAV2-injected retinas show fluorescence mainly in the 
RGC with fewer GFP-positive somas in the INL. Rare transduction of photoreceptors could be 
observed (arrow).  (c) FISH substrate was applied three times to maximize sensitivity and 
detected the location of transgenes within the retina. Arrowheads highlight GFP transgenes in 
the retina. Scale bar = 20 m. RGC, retinal ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer. Graph is shown with error bars indicating the standard error mean (SEM) 










Figure 2.5 Intravitreal delivery of high-titer rAAV2 capsids resulted in transduction only in 
the presence of HS binding 
Fundus images of eyes injected with 2x109 vg rAAV2 or rAAV2-R585E vector were collected at 
8 weeks following delivery. Transduction with rAAV2-R58E is absent, but rAAV2 shows a diffuse 






Figure 2.6 Subretinal transduction of rAAV2 capsid variants mixed with vitreous to 
confirm vitreous did not inhibit transduction 
Vector solution was preincubated with equal volume of vitreous collected from mouse eyes for 1 
hour before being injected. Transduction of RPE was seen with both rAAV2 and rAAV2-R585E, 







Figure 2.7 FISH of intravitreally injected eyes three days post-injection 
PBS-injected eyes served as a negative control for FISH detection and had low background. 
Arrowheads are used to highlight FISH signal and aggregation at ILM are shown in black arrow. 





Figure 2.8 Schematic of the binding difference between capsids over time in the retina  
The trafficking of IVIT-delivered AAV particles is shown on the retina (gray). Vector can be 
found in few numbers in the retina soon after delivery regardless of HS binding. Over time, the 
HS-binding vectors (blue) accumulate at the ILM to further penetrate the retina whereas non-
HS-binding capsids (yellow) remain mostly in the vitreous. HS, heparan sulfate; ILM, inner 
limiting membrane; RGC, retinal ganglion cells; INL, inner nuclear layer; ONL, outer nuclear 






Figure 2.9 Staining of HS in the retinas of multiple animal models. 
Retinas of mouse, rabbit, non-human primate, and human are shown. Each animal retina has 
been stained with secondary antibody only (without antibody) and with an antibody specific to 
HSPG (with antibody). Intense staining is seen at the ILM in all animal species and is not 
present in the negative control. Scale bar = 50 m. RGC, retinal ganglion cell layer; INL, inner 





Figure 2.10 qPCR analysis of viral binding to human retinas ex vivo. 
Results are quantified as vector genomes per cell genome. rAAV2 vector shows the greatest 
presence at the retina with few transgenes found elsewhere. The presence of transgenes 
delivered by rAAV2i8 were low in all collected tissues but showed a significant increase 






         
Figure 2.11 GFP fluorescence following IVIT delivery of HS-binding variants of rAAV1 
eight weeks post-injection. 
(a) Images show representative fundus and fluorescence of eyes treated with rAAV1 capsid or 
rAAV1-E531K capsid. Quantification of fundus images shows a 3-fold increase with rAAV1-
E531K capsid compared to rAAV1 capsid. (b) GFP IHC of retinal sections eight weeks after 
injection of rAAV1 and rAAV1-E531K capsids. Images show the co-localization with Müller glia 
(arrowheads) and non-Müller glia (arrows). Confocal z-stack images were compressed and 
displayed as the maximum projection. Scale bar = 50m. RGC, retinal ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer. Graph is shown with error bars indicating the SEM 




Figure 2.12 Analyses of HS-binding variants of rAAV6 eight weeks after IVIT delivery. 
Images show typical fundus and fluorescence of eyes treated with rAAV6 capsid or rAAV6-
K531E capsid at a low titer of 5x107 vg. Punctate expression around the retinal vessels could 






Figure 2.13 In vitro competition assay using soluble heparin to block the transduction of 
rAAV of HEK293 cells. 
Viruses were incubated with increasing doses of soluble heparin and applied to cell culture at a 
multiplicity of infection of 10,000 vg per cell. rAAV2 displayed a dose-dependent decrease in 
transduction which was not observed with either rAAV1 or rAAV1-E531K. The amount of 






Figure 2.14 Analyses of HS-binding variants of rAAV8 eight weeks after IVIT delivery. 
Images show typical fundus and fluorescence of eyes treated with rAAV8 capsid or rAAV8-
E533K capsid at a titer of 1x108 vg. Hazy expression could only be detected with HS-binding 
rAAV8-E533K capsid. Quantification of fundus images show error bars as the SEM and trend 






Figure 2.15 FISH detection of retinas injected with AAV serotypes and their HS-binding 
mutants three days after injection. 
The detection reaction was carried out twice and image levels were adjusted equally to enhance 
weak labeling. Transgenes found in the retina were more abundant with eyes injected with the 
HS-binding motif compared to their natural serotypes. rAAV8-E533K capsid could be seen 
accumulating at the ILM in addition to its presence in the retina. PBS-injected retinas had 
minimal background signal. Scale bar = 20 µm. RGC, retinal ganglion cell layer; INL, inner 




Figure 2.16 Transduction of rAAV2.5 in mouse retina 





Figure 2.17 Transduction pattern of rAAV2.5 is recapitulated using a single point mutant 
rAAV2-265D 
Fundus bright field (left) and GFP (right) are shown 8 weeks after IVIT delivery to an adult 
mouse. GFP fluorescence can been prominently seen around the retinal vessels with punctate 



















Figure 2.20 IHC of NHP retinal tissue following rAAV2.5 delivery 
SR, subretinal; IVIT, intravitreal; INL, inner nuclear layer; ONL, outer nuclear layer; POS, 

















Figure 2.23 Stereographic Roadmap projections of engineered glycan receptor footprints 
as viewed down the threefold symmetry axis on different lab-derived, synthetic AAV 
strains. 
The threefold symmetry axis is shown in the cartoon inset. Only surface exposed amino acids 
are shown, with each residue boundary depicted in black. The green regions depict the spikes 
on the threefold surface, while the blue regions represent the surrounding depressions. (a) 
Residues colored in orange depict engineered residues on AAV2i8; (b) yellow residues depict 
the HS footprint and pink residues depict the GAL footprint engineered on the dual glycan 
binding AAV2g9 strain; (c) pink residues depict the GAL footprint engineered onto AAV2i8 to 
generate AAV2i8g9; and (d) pink residues depict GAL footprint engineered on AAV8g9. 
Reprinted from Current Opinion in Virology, Vol 18, V.J. Madigan and A. Asokan, Engineering 





Figure 2.24 rAAV2G9 transduction of the mouse retina. 
 
 




Figure 2.25 Fundus images of adult mice eight weeks after IVIT delivery of galactose-only 
binding capsids 







Figure 2.26 Galactose staining does not appear correlated to Müller glia 
 
 





Figure 2.27 GFP fluorescence of mouse eyes eight weeks after IVIT injection with 
rAAV2.5G9 
GFP fluorescence is shown in grayscale. Fundus images show the prominent transduction 
around the retinal vessels. Additional punctate fluorescence can be seen around the retina. On 
histology, this pattern correlated to Muller glia-specific transduction. RGC, retinal ganglion cells; 







Figure 2.28 Quantification of retinal transduction following IVIT delivery of various AAV 
capsids 










Figure 2.30 The engineered 7m8 capsid (rAAV2 + peptide) relies on HS binding for IVIT 
transduction 
rAAV2 was compared to a 7-amino acid peptide insertion in the context of either HS binding 
(rAAV2 + peptide) or no HS binding (rAAV2i8 + peptide). Without HS binding, there was no 








CHAPTER 3: Future directions 
3.1 HS binding motif 
The vector accumulation at the ILM is important for the ability of rAAV to transduce the 
retina following IVIT delivery. We showed that HS-binding motif on the rAAV1, 2, and 8 
promoted the accumulation of capsid at the LIM, presumably through the HSPG found at the 
ILM. The addition of the HS-binding motif onto other rAAV serotypes may enhance the 
transduction by IVIT delivery. The lack of accumulation by several AAV serotypes could be 
responsible for the limited transduction of the retina by IVIT. By simply graphing the HS-binding 
motif onto AAV capsids, their accumulation onto the retina may increase and lead to 
transduction not seen by the parental capsid. First, it would be interesting to graph the HS-
binding motif onto rAAV4 and rAAV5 capsids because of their tropism by SR injection. By SR 
delivery, rAAV4 shows restricted transduction of RPE {Weber 2003} and rAAV5 is efficiently 
transduced to the PRs along with RPE transduction. Although the transduction pattern by these 
capsids may simply be the result of the route of administration, it is more likely is that they show 
retinal cell-specific transduction, but cannot access these cells by IVIT delivery. This idea seems 
valid given the ability of IVIT rAAV5 to transduce the PRs when the ILM is altered [49, 50]. 
Staining for pan-SIA expression using wheat germ agglutinin indicated that SIA is abundant in 
the outer retina, though specific staining of either the 2,3 O-linked SIA or 2,3 N-linked SIA would 
help to provide a mechanism for the tropism of these serotypes. The lack of IVIT transduction by 
these capsids may be due to the lack of accumulation at the ILM, which would keep the vector 
diluted in the vitreous. By increasing the accumulation of these serotypes at the vitreoretinal 
junction, the capsids are no longer diluted in the vitreous and would be primed to penetrate the 
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retina. In addition to the accumulation out of the vitreous, the vector must be able to penetrate 
the retina to reach the outer retina. Given that several studies have shown the LIM to be the 
bottleneck to IVIT retinal transduction, we would assume that the penetration of vectors would 
not be an issue.  
An additional capsid that would be interesting to test for enhanced transduction would 
the rAAV9. Within the context of neuroscience applications, rAAV9 has become the gold 
standard to use [80-82]. rAAV9 has been shown to cross the blood-brain barrier when delivered 
intravascularly in adult mice [83]. The age at which rAAV9 is delivered can change the 
transduction profile [84, 85]. When the vector is delivered to neonatal mice, transduction within 
the retina can be detected, indicating that rAAV9 may be capable of passing through the blood-
retinal barrier as well [86-88]. This capability to pass through these barriers may endow it with 
the ability to pass through the ILM and penetrate the retina efficiently. In fact, when FISH was 
carried out on IVIT-delivered rAAV9, we found the presence of transgenes within the retina but 
did not lead to detectable transduction (data not shown). Perhaps additional mechanisms are at 
play and must be satisfied to promote transduction within the retina.  
Many researchers have tested various AAV capsid libraries to look for a variant that 
would be ideal for individual applications. One way to generate a library with high diversity is by 
using large fragments of the cap gene from the various serotypes to ligate together to form a 
unique construct of cap sequence [89]. To further add diversity, capsid libraries can be 
subjected to error-prone DNA polymerase to introduce point mutations within the fragmented 
cap gene sequence. This approach can disrupt the motifs on the capsid needed for receptor 
binding and intracellular trafficking leading to new transduction patterns. Through in vivo 
selection, capsids are selected for their ability to bind to cells of interest, not necessarily for their 
transduction. However, this selection may exclude capsids with interesting transduction 
potential but had a disruption in a beneficial motif (e.g. HS motif for IVIT rAAV transduction). If 
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the accumulation at the ILM remains the bottleneck, the number of clones recovered will be 
reduced. Therefore, when creating the library, there should be a large proportion of vector that 
have HS binding. This does not mean that the library should be made and then separated 
based on the capsid’s ability to bind to an HSPG column but rather that HS-binding motifs 
should be incorporated into the generation of the library to yield more viable clones that can 
overcome tissue barriers. 
Another way to add an immense amount of diversity is to insert a peptide within the 
rAAV capsid that is known to lead to transduction [90-93]. So long as the peptide isn’t inserted 
in a binding motif needed for transduction, the peptide could increase viral interaction with the 
cell or boost the virus trafficking in some way. Because rAAV2 can transduce cells independent 
of HSPG binding, peptides are often incorporated to ablate HSPG binding so that the native 
receptor binding does not dominate the novel transduction profile [91, 92]. The crystal structure 
and mutational analysis have led to a map of the rAAV2 cap sequence that tolerates a peptide 
insertion [91, 94]. This rationale was used to generate the capsid library tested for enhanced PR 
transduction. However, the insertions also disrupted the ability of the rAAV2 capsid to bind to 
HSPG [95]. From this model, we would suggest that this peptide would be best served by 
placing it away from the HSPG-binding motif on the base of the threefold axis of symmetry to 
another capsid positions [94, 96]. Large peptide ligands have been inserted into VP2 to prevent 
disruption of VP3 yet can still be surface exposed to alter cell surface interactions [97, 98]. By 
using a HSPG-binding rAAV2 capsid and placing the peptide away from this motif may yield a 
novel peptide that leads to transduction of a specific cell type.  
3.2 Trafficking studies of all serotypes 
This was the first study using ISH to detect rAAV in the retina. Previous experiments 
have used fluorescently-labelled capsids to detect trafficking of rAAV particles [49, 50]. The 
fluorescent label attaches to lysine residues on the capsid surface, where they may interfere 
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with native binding to receptors. The lysine is involved in enhanced transduction in rAAV1-
E531K, and by covering the charged residues on rAAV1. Dalkara et al. (2009), did not see 
rAAV1 binding or transduction however we saw rAAV1 transduction in our experiments. In 
addition to this experimental setback, the entire set of rAAV serotypes has yet to be tested for 
trafficking differences in the retina. Because transduction is not indicative of trafficking, ISH 
studies would help the field to understand the barrier encountered by each of the serotypes. 
From the ISH detection of the panel of rAAV, some serotypes may show accumulation without 
HSPG binding which will offer additional receptors to target to further increase IVIT transduction. 
 To carry out these experiments, each of the rAAV serotypes could be IVIT injected into 
mice and eyes enucleated soon after delivery. It would be beneficial to embed the entire eye in 
paraffin so that vector that remains diluted in the vitreous can still be assayed. Our FISH studies 
conducted were carried out on cryosections with the lens removed. We tried to perform 
cryosections on whole-embedded eyes, but the hard structure of the lens disrupt morphology. 
Therefore, the lens, was removed prior to embedding which would also the vitreous. The 
difference in embedding would require additional protocol optimization, but would provide the 
most accurate picture of rAAV trafficking in the retina. 
It would be important to determine trafficking studies of SR-delivered rAAV vector to 
parse out by what mechanism SR transduction occurs. It may be that vectors transduce the 
outer retina because of tropism or because the virus is concentrated proximal to cells they 
transduce. With some serotypes like rAAV5, there appears to be a tropism to the PRs since 
both IVIT and SR delivery lead to transduction of the outer retina. The bolus delivery in the SR 
space effectively concentrates the vector under the retina, similar to how the aggregating 
vectors at the ILM can transduce the retina by IVIT. To determine if a concentration effect is 
responsible for transduction, 1 µl of varying amount of vector could be delivered SR and 
assessed over time to determine the minimal amount of vector needed for transduction. From 
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our results in Chapter 1 of this dissertation, 1 µl of 2E9 vg can spread over the entire retina. 
Using ISH soon after SR injection to determine the trafficking of vectors would be similar to the 
ISH assessment by IVIT. With ISH, the location of vector can be determined irrespective of 
promoter strength and expression kinetics 
Currently, to achieve the highest expression of the transgene, the vector must be 
delivered subretinally. Issues arise with this injection route when considering treatment for 
patients with extremely fragile retinas due to advanced degeneration. SR delivery is a balancing 
act between delivering enough vector to adequately spread and transduce a large part of the 
retina, but not delivering too much volume as to make the retinal detachment unable to resolve 
on its own. This makes it difficult to treat an entire retina by SR delivery and there is no standard 
protocol to determine what area of the retina to treat. ISH analysis may determine the amount of 
vector, rather than volume, to be the determine factor of spread. Studying the trafficking of rAAV 
by SR delivery will allow for the design of vectors with better spread and transduction of the 
retina.  
Similar to the results seen with SR delivery in mice, transduction of vector is most 
prominent in the region of the detachment with lesser transduction outside this area. Therefore, 
an ideal SR AAV vector should can spread farther than the detachment. Similar to how HS 
binding aggregates AAV onto the ILM, capsid interaction with glycans found in the outer retina 
could aggregate vector and prevent the dissemination across the retina. These glycans may be 
more exposed during the detachment of the retina. From our experiments, we know that binding 
to HSPG does not influence the SR transduction of rAAV2, likely since HSPG staining did not 
show abundant staining in the outer retina. This would also help to explain why HS-binding 
rAAV8-E533K did not perform better than the rAAV8 parent capsid. In contrast, the addition of 
additional glycan interactions on an AAV capsid may promote the spread of vector across the 
outer retina. From our experiments, we found sialic acid and galactose to be abundant in the 
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outer retina. It would be interesting to subretinally deliver vectors that have dual glycan binding 
ability and observe any changes in vector spread. 
Although SR delivery results in greater transduction compared to IVIT delivery, many of 
the issues with the SR injection can be circumvented via IVIT injection. We provided evidence to 
suggest that HS binding promotes the accumulation of vector out of the vitreous and onto the 
retina, where it can later transduce the retina with greater efficiency. Not only does the ILM 
serve as a barrier to retinal transduction, but the delivery of vector to the vitreous leads to a 
dilution of the vector and reduces its transduction potential. From our studies, we found that the 
small size of the mouse eye is particularly effective at increasing the interaction of AAV with the 
retina. However, in a large eye of a NHP, a high concentration of infectious AAV can be found in 
the vitreous weeks after IVIT delivery. Similar to the work done with mice, we did not identify an 
inhibitory molecule in the vitreous of NHP to explain the lack of transduction. It can be difficult to 
parse out whether the larger volume of the NHP vitreous, the increased thickness of the NHP 
ILM, or a combination of both are responsible for the limited transduction of IVIT AAV.  Recent 
publication of successful AAV transduction in the NHP retina following a sub-ILM delivery 
indicates that at least the ILM does play an inhibitory role in the IVIT transduction of AAV. 
Dosage studies in the NHP also indicate that dilution is likely a factor for the limited transduction 
of the retina. Promoting greater interaction of AAV capsid with the retina becomes an important 
attribute for an ideal IVIT AAV vector. This can be carried out through glycan binding as 
described in the earlier chapter. A more detailed study on the kinetics of vector trafficking in the 
retina would help to explain the rate-limiting steps to viral transduction by either SR or IVIT 
delivery. 
Several research groups have used a panel of AAV serotypes and characterized these 
capsids based on their ability to transduce the retina. However, it is becoming increasing clear 
that viral transduction and viral distribution are not synonymous terms. This is most evident in 
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the transduction differences between single-stranded and self-complementary rAAV2 by either 
IVIT or SR delivery. The use of various promoters can also yield results that are incongruent 
with previous analysis of that certain capsid serotypes were not retinal tropic. We tried to 
optimize the expression of GFP by using a robust promoter (CBh) in a self-complementary 
transgene form. Therefore, we would test the transduction of the scAAV-CBh-GFP panel, as 
well as carry out ISH studies. 
3.3 AAV accumulation at the ILM  
Another method to help reduce the dilution of delivering vector to the vitreous is to 
remove the vitreal fluid prior to injection. This procedure has been performed in dogs with mixed 
outcomes [99] but overall results seem promising [100]. This would ensure that the vector 
remains concentrated. The dilution in mouse vitreous would not be as much of a factor due to 
the small volume. Vitrectomy in NHP can lead to dramatic transduction in as little as 20 days 
post-injection whereas no expression is seen without vitrectomy even when observation is 
extended to 60 days post-injection [100]. Although performing a vitrectomy is a relatively simple 
procedure, it would dramatically affect the distribution of vector. Most likely, delivered vector 
seems to pool at the lowest point of the globe and result in intense focal transduction. Spreading 
the vector around the entire retina may be as simple as rotating the head in various positions 
and inclines for several minutes. The vitrectomy protocol may also allow for a greater volume to 
be delivered. Typically, up to 150 µl has been delivered to the eye for transduction, but volumes 
up to 1 ml have been tested and shown to be effective. While the volume of vector can be 
important, more likely it is the amount of vector that provides the greatest impact. Most rAAV 
capsids can be scaled up to produce high titered virus, but there may be capsid mutants or 
production issues which limit the amount of vector that can be production. It is unclear from 
current studies what mechanism AAV uses to traverse the retinal layers and identification of this 
mechanism may lead to novel AAV capsids with greater spread. Only by understanding the 
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small nuances of AAV retinal trafficking will we be able to exploit these mechanisms for the next 
generation of AAV capsids with greater IVIT transduction properties.  
It may be possible that graphing an HS-binding motif may not work in all rAAV 
serotypes. Some capsid may bind with low affinity to HSPG and thereby reducing aggregation. 
Another way to achieve greater AAV presence at the retina could be through the use of 
microbubbles. Microbubbles are compounds that can be coupled to protein or DNA and can be 
loaded with rAAV particles [101]. Ultrasound destruction of microbubbles can enhance rAAV 
transduction [102, 103] through an increase in clathrin endocytosis [104, 105]. These 
microbubble-rAAV can be herded to specific regions through the use of low-frequency 
ultrasound [106, 107]. Once at the ILM, the change to ultrasonic frequency causes the 
microbubbles to burst to release rAAV. This would also temporary disrupt the ILM to increase 
vector penetration into the retina. When microbubbles were administered intravenously, the 
blood-brain barrier could be focally targeted in mouse brains [108, 109] or targeted to other 
tissue by redirecting ultrasound [110]. In this way, microbubbles coupled with AAV could be 
delivered to the vitreous, pushed to the ILM by low-frequency ultrasound, and released at the 
retina via high-frequency ultrasound. Because the burst of the microbubble can disrupt cell 
membranes to aid in the intracellular uptake of drug, the breaking of the microbubbles at the 
ILM may disrupt the membrane and increase the penetrance of AAV across for enhanced retinal 
transduction. 
3.4 Further characterization of rAAV2.5G9 
The specific and enhanced transduction of the rAAV2.5G9 vector was shown to be a 
combination of both motifs on the rAAV2 capsid. However, the exact mechanism that produced 
this pattern is not yet resolved. We hypothesized that staining for galactose would yield a 
pattern that explained the phenotype, but there was no staining on the inner retina and fain 
expression in the ONL. Certainly, we did not observe a co-localization with Müller glia (Figure 
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2.26) to explain the specific tropism of rAAV2.5G9. It would be beneficial to perform flat-mount 
staining of glycans to find new glycan targets. We would hypothesize that the motifs on the 
capsid lead the virus to accumulate on the ILM differently than the parental rAAV2. 
 ISH analysis on whole-mount retinas just days following injection would provide 
evidence to constructing a model of rAAV trafficking. By performing confocal microscopy on flat 
mount retinas, a 3D representation of the retinal section could be obtained. We attempted this 
type of analysis on whole-mount retinas at three days, one week, and two weeks post-
administration; however, we found retinal curling to be the biggest issue. A methods publication 
of whole-mount ISH on developing mouse vasculature gene targets in the retinas has shown 
methanol fixation and minimal hybridization media can maintain retinal flatness [111]. We 
incorporated this method into our protocol, but retinal curling continued to be an issue. 
Therefore, additional optimization of this combined protocol is necessary to assess retinal 
trafficking of the chimeric rAAV2.5G9 capsid. ISH analysis over time on rAAV2.5G9-injected 
whole-mounts would likely show vectors found all along the inner retinal surface, but 
concentrated along the retinas where transduction later occurs. With a combination of FISH and 
IHC, it would be possible to observe the aggregation around the retinal vessels and potential 
retinal penetration via cellular scaffolds 
It would be interesting to test the rAAV2.5G9 capsid in a large animal model to confirm 
the phenotype observed in mice is conserved. Often vectors which show great transduction in 
the mouse model fail to produce the same phenotype when translated to another animal model. 
Both the size of the eye and the thickness of the ILM differ substantially between small (e.g. 
mouse, rat) and large (e.g. rabbit, primate) animals. This lead us to do translational experiments 
in ex vivo human retinas and in vivo testing of rabbit and NHP eyes. The rAAV2.5 transduction 
surrounding retinal vessel in rabbit eyes provided evidence of a conserved tropism across 
animal models. Future IVIT NHP experiments would be carried out for three months or longer 
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similar to duration lengths in other NHP retinal studies [100, 112]. The ISH data on NHP retinas 
to confirm that vectors had accumulated at the ILM, but it was unclear from the experiment 
whether the capsid had insufficient time to penetrate through the retina or if the ILM of the NHP 
proved too great of a barrier.  
The unique transduction of the rAAV2.5G9 motif be of benefit to disorders involving 
neovascularization or some vascular component. Whereas previous research using canonical 
rAAV2 may have resulted in sub-optimal transduction, the 265 position in the rAAV2.5 motif may 
provide new vectors with greater therapeutic benefit by maximizing transgene expression 
around vessels. We tested the ability of rAAV2.5 to deliver Nrf2 transgenes to reduce reactive 
oxygen species following photodamage to the retina {Liang 2016}, but did not directly compare 
to rAAV2 capsid. 
3.5 Creation of a super capsid for retinal transduction 
  The AAV vectorology field has advanced rapidly, creating various capsid mutants to 
capitalize on specific aspects of viral trafficking. Often these mutations are to enhance various 
intracellular trafficking steps, alter spread, or influence tropism. However, the field has yet to 
bring all these mutations into a single capsid. Such a “super capsid” may provide supreme 
transduction that surpasses the enhancement of each mutation on its own. As stated above, 
rAAV transduction of a cell is a multi-step process (cell attachment, intracellular trafficking, 
endosomal/proteasomal escape, nuclear entry, uncoating) with additional steps added in the 
trafficking across the retinal tissue (ILM accumulation, retinal penetration, spread). The addition 
of the HS-binding motif would work to increase the amount of vector accumulating onto the ILM 
from IVIT delivery. Once at the retina, additional motifs to glycans in the outer retina may 
enhance the penetration of vector. The recent addition of the peptide in rAAV2, known as 7m8, 
works by increasing vector entry into the cell [72]. Once in the retinal cells, Tyr mutations in the 
capsid would help vectors avoid proteasomal degradation [71]. Factors like NLS may help to 
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further promote the vector reaching the nucleus [113]. The rAAV8 serotype is faster in uncoating 
than rAAV2 [87] and the ability of rAAV8 to outperform rAAV2 and rAAV5 in retinal transduction 
[114]. Most of these modifications are serotype independent, and because these mutations work 
on different mechanisms, they may synergize the transduction of the rAAV capsids. 
3.6 Avoidance of rAAV neutralizing factors in the vitreous 
If retinal gene therapy is to progress in its clinical relevance, it must address the 
avoidance of the immune system. A drawback of delivering vector to the vitreous is the potential 
inhibition by neutralizing antibodies [115]. Capsid or capsid mutants, like rAAV2.5, avoid 
interaction with neutralizing antibodies [65] and; therefore, would be a great candidate for 
patients with pre-existing rAAV2 neutralizing antibodies. Testing of the serum for neutralizing 
antibodies is indicative to the antibodies in the vitreous [115]. Development of novel capsids, 
like the evolutionary ancestral capsid [116]. A potentially better protocol to circumvent the 
neutralizing response is to supply empty capsids en mass to “soak up” antibodies [117]. The 
efforts to avoid neutralizing antibodies in the patients using novel capsid mutants that continue 
to show transduction of desired cells require further research. 
3.7 Progress of retinal gene therapy 
The future directions above have dealt with the capsid, but these novel capsids can be 
used to carry therapeutic transgenes to treat loss-of-function genetic diseases Gene 
supplementation therapy effectively treats these types of diseases like LCA; however, a more 
generalized therapy would ease the burden of individualized pharmacogenomics medicine. A 
mutant-independent strategy could augment current treatment which is reporting worsening 
degeneration in some patients as the disease continues to progress [118-120]. Gain-of-function 
or dominant negative mutations would benefit from genome editing strategy. These strategies 
work best before degeneration of cells and circuitry. In cases of late-stage disease progression, 
conversion of retinal cells to PRs or repopulation of PRs are the best option. 
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 Delivery of neurotrophic factor 
Several neurotrophic factors have been studied for retinal preservation in genetic rodent 
retinal degenerative models. For example, GDNF has prevented the loss of retinal cells in both 
an rd mouse model and RP rat model [121-123]. The use of the rAAV2.5G9 capsid to deliver 
GDNF transgenes to Müller glial cells superior transduction to the Müller glia-specific rAAV6 
mutant known as rAAVShH10. Comparing rAAV2.5G9 transduction to rAAVShH10 in an rd 
mouse model may indicate the new vector is capable of rescue at lower vector titers. Either 
way, the ability to use two serologically independent capsids with identical tropism will be 
beneficial in the treatment of both eyes for patients. Benefits have been observed using BDNF 
as well [124-128]. However, not all neurotropic factors are therapeutic. The delivery of the 
neurtin neurotropic factor was unable to functionally rescue the PR-degenerative rd mouse 
model [96] and CNTF has had varying therapeutic effects [129-133]. 
 Induction of retinal regeneration  
Another strategy to deal with the loss of PRs is to repopulate the retina with stem cells 
[134-137]. One way of doing this is through the SR delivering of RPC to the outer retina. 
However, Müller glia retain stem cell properties [138] and are great cell target to convert into 
RPC because the Müller glia are not degenerated in diseases. Retinal development may lead 
insight into another approach that could be used to reconstruct the retina. During development, 
RPC rise to the numerous cell types that exist in the retina before terminally differentiating into 
the Müller glia. By coaxing the Müller glia back into its undifferentiated state, these cells may 
repopulate the retina in areas of major PR death. Once the retina has been repopulated, that 
these induced cells would continue their natural lineage back to Müller glia. Because Müller glia 
span the entire thickness of the retina, they are easily targeted by IVIT delivery of rAAV2.5G9, 
further eliminating the disruption of the retina by SR delivery. However, the disruption of OLM 
could help integration stem cells similar to OLM disruption but other means [139, 140]. Stem cell 
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integration into the retina still requires further optimization [132] and the use of neurotropic 
factors can improve integration and survival [141]. The use of patient-derived stem cells would 
avoid possible immune-related issues to stem cell transplants [142, 143]. The four transcript 
factors needed to induce pluripotency (Oct4, Sox2, Klf4, c-myc) in differentiated cells [144] may 
be used to generate the in vivo stem cells from Müller glia. Transgenes for these transcription 
factors are not likely to fit into the small space of a single AAV vector; however, vectors 
packaging each of the factors could then be combined during injection to convert Müller glia. By 
inducing stem cells in an intact retina, the correct environment for differentiation should be 
satisfied rather than using Matrigel [145, 146]. Several labs are currently working on converting 
patient-derived fibroblast into iPSC and then coaxing these cells to devolve into a retinal state 
using media and Matrigel. Because SR-delivered stem cells are capable of migrating and 
establishing connections on their own, it is likely that iPSC will also be able to migrate to the 
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